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ABSTRACT

Cystic fibrosis (CF) is a genetic disorder with a median survival age of 40.7 years. Chronic
airway inflammation and dehydration are critical features of CF. The size and structure-dependent
hydration and anti-inflammatory properties of glycosaminoglycans (GAGs) such as hyaluronic
acid (HA) may help ameliorate these symptoms. The GAGs contained in farmed Alligator
mississippiensis by-products offer a potential to improve waste management practices and increase
revenue in the alligator industry, through their development for use in biomedical applications.
This study aimed to efficiently extract and characterize GAGs from alligator carcasses (ACS),
backstraps (ABS), feet (AFT) and eyeballs (AEB), to evaluate their effects on CF-like airways exvivo. Samples were collected from local alligator processing facilities and extractions were
conducted according to a randomized complete block design. The contents of sulfated and nonsulfated GAGs were determined using dimethylmethylene blue and HA ELISA assays,
respectively. Total GAG content was confirmed by the carbazole reaction assay. Protein content,
mineral content and molecular weight (MW) were determined by the bicinchoninic acid assay,
inductively coupled plasma and 0.75% agarose electrophoresis, respectively. FTIR spectroscopy
was conducted to fingerprint the structures of the extracted GAGs. Multi-step processes for the
extraction of GAGs from alligator by-products were developed and ABS had the highest (p≤0.05)
total GAG content (15.53±0.27 mg/g), followed by AFT (4.72±0.05 mg/g), AEB (0.79±0.01 mg/g)
and ACS (0.60±0.00 mg/g). These results are equivalent to ~2.13 g GAGs per harvest-size farmed
alligator or an estimated GAG production of ~0.73 tons/year in Louisiana. The GAGs in all
samples were predominantly (>97%) HA with a poly-disperse MW of up to 1600 kDa. FTIR
revealed spectra showing characteristic GAG features such as -OH, -NH, -CH and amide signals

xiv

from residual protein, comparable to previous studies on animal-sourced GAGs. Ex-vivo gene
expression analysis of Scnn1b-Tg mice tracheal epithelial cells indicated that AEB GAGs (0.5
mg/12 mm insert) have the potential to regulate the expression of genes which may aid in restoring
the protease/anti-protease balance, reducing inflammation, and regulating ASL osmotic
homeostasis. Alligator GAGs may also aid in the treatment of other inflammatory conditions such
as wound healing and arthritis in humans and animals.

xv

CHAPTER 1
INTRODUCTION

The state of Louisiana has the largest alligator (Alligator mississippiensis) industry in the
United States. A total of over 350,000 farm-raised and wild alligators are harvested yearly through
a world-renowned sustainable system managed by the Louisiana Department of Wildlife and
Fisheries. This model generates a significant revenue, as well as protection of the wetland habitats
[1]. In the processing of slaughtered alligators for their skin and meat, the industry generates waste
which is currently being disposed in landfills or marketed at very low prices. These by-products
contain valuable anti-inflammatory glycosaminoglycans (GAGs) that can be extracted in a
promising effort to improve current waste management practices and further increase the
industry’s value.

Hyaluronic acid (HA) is a linear, negatively charged, highly hydrophilic and non-sulfated
GAG found mainly in the extracellular matrix (ECM) in the form of sodium salt [2,3]. This high
molecular weight (HMW) GAG, which is degraded by hyaluronidases (HAases), chondroitinases
(ChrAses) and reactive oxygen species (ROS), possesses multiple size-dependent signaling
properties. There is consensus that larger HA chains have anti-inflammatory properties and smaller
ones have pro-inflammatory activity, however there is no clear categorization about the molecular
weight of HA [4–6]. HA fragments (6-12 disaccharides) have been reported to significantly
increase the expression of inflammatory cytokines and tissue degrading enzymes such as matrix
metalloproteinases (MMP) [7]. In the airways, HA interacts with a variety of cell surface receptors
and HA-binding proteins to activate intracellular events through various pathways [8,9].
Inflammation in mice cystic fibrosis (CF) airways has been effectively mitigated by nebulized HA
1

as measured by the reduction of TNF-α, myeloperoxidase activity, ROS and tissue
transglutaminase (TGAse) activity [10]. Moreover, Scuri and Abraham reported dose dependent
inhibition of human NE induced airway responses in sheep pretreated with 150 or 300 kDa HA
[11]. It has also been proposed that the water binding properties of HA may increase the elasticity
of lung elastic fibers, thus improving pulmonary mechanics [12] or purulent mucus clearance. The
abundance of carboxyl groups in HA may also result in an interaction with Ca2+ [13,14], therefore
limiting TGAse inflammatory activity in the airways of CF patients.

CF is a severely life shortening genetic disorder that globally affects around 70,000
individuals primarily of Caucasian descent. Mutations in both copies of the CF transmembrane
conductance regulator (CFTR) gene disrupt normal production of the CFTR protein which is a
chloride channel expressed in the epithelium of multiple organs including the lungs [15]. The
defective CFTR results in abnormal transport of chloride and sodium across the cell membrane
which leads to a high morbidity due to obstructive lung disease [10,15,16]. CF is also characterized
by an early and dysregulated inflammatory scenario in the airways which has been associated with
increased levels of pro-inflammatory cytokines and enzymes [17–21]. The extent of inflammatory
response in these patients is disproportionately increased compared to patients without CF both in
presence or absence of bacterial infection [22]. Upregulation of nuclear factor kappa beta (NF-κβ)
increases the production of interleukin-8 (IL-8) and tumor necrosis factor alpha (TNF-α), which
mediate neutrophil activity and the secretion of neutrophil elastase (NE), a serine protease
designed for bacterial phagocytosis but that can also degrade airway tissues and cause lung damage
[18,23,24]. Currently, anti-inflammatory treatments with corticosteroids and high-dose ibuprofen
have shown benefits, however side-effects limit their continuous use [25,26]. Furthermore, TGAse
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is an enzyme that catalyzes cross-links or deamidation of target proteins in the presence or absence
of Ca2+ [27,28] and it has been shown that innate increased oxidative stress in CF airway epithelia
induces TGAse up-regulation. For this reason TGAse has been recognized as a potential target
enzyme for healing of lung inflammation and injuries [29,30].

HA is a natural component of the respiratory system that has been safely used in European
CF Centers to improve the tolerability of hypertonic saline and to test its efficacy in the treatment
of bacterial rhinosinusitis in combination with tobramycin [24,31,32]. Globally, the HA market is
estimated over US$1 billion in the biomedical (knee osteoarthritis, ophthalmic procedures and
dermal fillers), cosmetic and food industries [33,34]. This compound alone or in the presence of
other GAGs may aid in the down-regulation of the chronic and uncontrolled pro-inflammatory
responses in CF by reducing the expression of potent cytokines and TGAse. In aggregate the
currently available information on CF, GAGs, and the abundance of waste products containing
GAGs in the Louisiana alligator industry, support the relevance of extracting A. mississippiensis
by-product GAGs to evaluate their potential to ameliorate inflammation, mediate osmotic
homeostasis, and recover the protease/anti-protease balance in CF airways, as well as potentially
generate economic development through increased revenue and creation of new labor and high
technology jobs.

The main objective of this research was to determine the yield and biochemical
characteristics of A. mississippiensis by-product GAGs and explore their potential regulatory role
on a selected panel of genes associated with CF in mice CF-like airways ex-vivo. The specific aims
that derive from this objective are:
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1. To develop a method for the extraction of GAGs from alligator carcasses (ACS), feet
(AFT) and backstraps (ABS).
2. To develop a method for the extraction of GAGs from alligator eyeballs (AEB).
3. To quantify and characterize the GAGs extracted from ACS, AFT, ABS and AEB.
4. To evaluate the effects of A. mississippiensis AEB GAGs on the ex-vivo expression of
selected genes in Scnn1b-Tg mice tracheal epithelial cells (MTEC).
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CHAPTER 2
LITERATURE REVIEW

2.1.

Louisiana Alligator Farming
American alligators (Alligator mississippiensis) have been used commercially for their

valuable leather since the 1800s and their harvest was generally unregulated through the 1900s.
This resulted in severely reduced harvests in the 1950s and a hunting ban from 1962 to 1972 [35].
Since 1972, Louisiana alligators have been managed as a commercial, renewable natural resource
by the Louisiana Department of Wildlife and Fisheries through a successful and world renowned
sustained use program. The program regulates harvest, assures long term benefits to the survival
of the species and provides significant economic benefits and incentives to private landowners to
protect alligator wetland habitats [36]. After rebuilding the population through research,
management and law enforcement in the 1960’s, the wild harvest from 1972 through 2014
produced over 975,000 wild skins. Currently, most of the A. mississippiensis farming activity
occurs in the southeastern United States and it is led by Louisiana [37] which supplies ca. 20% of
the global commercial crocodilian skins [38]. In January 2014, there were 34 licensed farms with
stock mainly in the Livingston, Terrebonne, Lafourche, St. Tammany and Vermilion parishes [36].
In calendar year 2014 alone, Louisiana sold 341,887 farm raised skins and 35,945 from wild
harvest. Including all skins, meat and egg collection the industry generated over $100,000,000 in
economic benefit to the state of Louisiana [39]. Singapore, Japan, Germany, France and Italy are
the main high-end markets for skins at an average $8.50/cm (width) in 2013, while the meat (~3
lb./alligator) is commercialized within the United States at an average of $7.00/lb. (2011-13) [36].
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Since 1986, alligator eggs have been collected from the wild between the months of June
and August to be incubated in private hatcheries. Eggs are incubated at ~30 to 34°C from 1.5 to 3
months [40]. Most of the hatchlings are raised for their hide and meat, however to maintain the
wild population stable, ~14% of the hatchlings are returned to the same location where they were
collected [41]. The remaining ~86% of the hatchlings are placed in different types of indoor
buildings (large round sheds, small rectangular sheds, etc.) under controlled air and water
temperature (80°F), animal density (1 ft2/ alligator of less than 24 inches long and 3 ft2/ alligator
of 25-48 inches long) and feeding conditions (diet with 45-55% protein) during 10 to 18 months.
After slaughtering alligators at market length (≥ 4 ft.) using approved methods, hide and meat
processors generate approximately 500 tons of by-products per year including ACS, AFT, ABS
and AEB that are currently disposed in landfill or sold at very low prices (1¢ per lb) for pet foods.
However, with increased regulations regarding pet feed, few animal feed processors are buying
these by-products. Efforts have been made to better understand and increase the profitability of
alligator carcasses and by-products [42], however little has been reported to date regarding feasible
opportunities. Teeth, heads and skulls are also used as tourist curios. To the best of our knowledge,
there are currently no processes or businesses established to utilize alligator by-products in a
profitable and sustainable manner.

2.2.

Medicinal Properties of Crocodilians
Since ancient times, zootherapy has been an alternative in the treatment of different

illnesses. “Medicine men” in different tribes around the world have used animal-based traditional
medicine for centuries. The folk medicinal use of crocodilians has been documented in populations
in Mexico, India, and Nigeria [43–45] which leads to investigation of the existence of therapeutic
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and bioactive compounds in these organisms. This becomes significant considering that these
reptiles have a low incidence of diseases in the highly contaminated conditions of marshes and
swamps and most of their wounds heal properly and completely [46]. Recently, studies conducted
in South Africa and the United States investigated the antimicrobial, amoebicidal, antiinflammatory and antiviral properties of crocodilian body parts [47–49]. These properties may
partially explain the evolutionary success of crocodilians while living in wild and farm aquatic
environments teeming with bacteria and/or agricultural residues [46,50,51].

Crocodile-based treatments play a role in the indigenous medicine of Nigerian
communities. Nile crocodile (Crocodylus niloticus) has been reported to be used in the treatment
of rheumatism (whole tail bones), snake poisoning (scales or tip of tail) and male impotency (whole
male animal) [44], although scientific proof is lacking and the placebo effect not tested. In a review
of traditional medicine in the state of Kerala, India, Padmanabhan and Sujana [43] reported the
use of Crocodile palustris eggs by tribal medicine men for asthma treatment. Even though the
GAG composition of crocodilian eggs has not been reported in detail, the presence of GAGs is
known [52]. Abundance of GAGs, including HA, has been reported in all components of the
chicken egg [53]. In China, crocodile bile is another folk medicine alternative remedy for asthma
and allergies [54]. The Chinese also believe that crocodile meat can help asthma sufferers, a person
getting a cold, and even improve the strength of the lungs [55], although such claims lack scientific
basis. Farmed crocodile tail oil has been evaluated for the treatment of microbial infections and
inflammatory conditions [47]. Buthelezi and others, showed that Staphylococcus aureus,
Klebsiella pneumoniae and Candida albicans are susceptible to 6-15% (w/v) oil preparations.
Furthermore, in an induced auricular edema mice model they showed that oral administration and
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topical application of crocodile oil resulted in optimal anti-inflammatory effects after 3 h and 12 h,
respectively. Many functional properties have been attributed to collagen and gelatin from
different animal sources [56] and it could be that other non-proteinaceous components of the ECM,
such as HA extracted along with the collagen may account for the claimed bioactivities.

It has been observed that American alligators (A. mississippiensis) often sustain serious
injuries and damage due to territorial disputes with other alligators. However, these reptiles exhibit
a remarkable ability to heal rapidly and without infection. In a cell based assay, serum collected
from wild alligators demonstrated antiviral activity against human immunodeficiency virus type 1
(HIV-1), West Nile virus and Herpes simplex virus type 1 (HSV-1). These and other reports by
Merchant and others suggest that alligators have evolved a complex innate immune system,
however other mechanisms such as the serum complement system are also active [48,49,57].
Antimicrobial peptides extracted from A. mississippiensis leukocytes have displayed antibacterial
activity against Gram negative and positive bacteria, antifungal activity against six pathogenic
Candida yeast spp. species and antiviral properties against HIV-1 and HSV-1 [58]. Four novel
antimicrobial peptides (leucrocins I-IV) were recently extracted and purified from Siamese
crocodile (Crocodylus siamensis) white blood cells [59]. Multivariate analyses of the serum from
all twenty-three known living members of the Crocodylia were tested for antibacterial activity
against eight bacterial species and it was revealed that the innate immune activities of the
Alligatoroidea were remarkable and statistically higher than those of the Crocodyloidea and
Gavialoidea [60]. This brief review demonstrates that there is evidence in favor of some potential
alligator-based medicine treatments, however more information must be generated to support these
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practices, determine the bioactive compounds responsible for the claimed effects and elucidate
action mechanisms.
2.3.

Hyaluronic Acid and Sulfated Glycosaminoglycans

2.3.1. Classification and Structures
GAGs are large heteropolysaccharides that are composed of repeating disaccharide units.
All GAGs are made of an amino sugar, typically n-acetylglucosamine (GlcNAc) or nacetylgalactosamine (GalNAc), and a uronic acid, typically glucuronic acid (GlcA). However,
there are two main types of GAGs. Sulfated GAGs include heparan sulfate (HS), of which heparin
(HP) is a highly sulfated member, which are based on D-GlcNAc and D-GlcA or iduronic acid
(IdA), respectively. Chondroitin sulfate (CS) is based on D-GalNAc and D-GlcA, while dermatan
sulfate (DS) is composed of D-GalNAc and L-IdA. Keratan sulfate (KS) is the most heterogeneous
GAG and is based on D-GalNAc and D-galactose. The non-sulfated GAGs include hyaluronan,
also called sodium hyaluronate or HA, and it is composed of D-GlcNAc and D-GlcA bound
together through β1,4 and β1,3 glycosidic bonds, respectively (Figure 2.1) [61–64]. Since HA is
the major non-proteinaceous component of the ECM [5] and consequently the most abundant GAG
found in alligator by-products, this literature review will focus mainly on HA’s features including
biosynthesis, degradation, biological properties, sources and applications.

2.3.2. Biosynthesis
HA is ubiquitously expressed in the ECM of the animal kingdom. It was first identified in
the vitreous humor of cattle eyes by Meyer and Palmer in 1934 [65]. In contrast to sulfated GAGs
that are produced in the Golgi apparatus, HA is synthesized at the inner face of the plasma
membrane as a free linear polymer not anchored to any proteins by three transmembrane glycosyl9

Hyaluronic Acid

Chondroitin Sulfate

Dermatan Sulfate

Keratan Sulfate

Heparan Sulfate*

Heparin

Figure 2.1. Repeating disaccharide units of the GAGs [Adapted from 10]. *HS
shows a lower degree of sulfation (0.6-1.5 sulfates/disaccharide) than HP (2.32.8 sulfates/disaccharide) [66].
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transferases or HA synthases (HAS1, HAS2, and HAS3) (Figure 2.2) [67]. Although these
isozymes synthesize an identical HA molecule, they have been shown to have distinct stability,
elongation rate of HA and Km values, which potentially regulate the biological function of HA [68].
HAS2 is the main HA synthetic enzyme in adult cells and it generates HA with an extremely large
and broad molecular weight distribution (>2000 kDa or a degree of polymerization around 5,000
disaccharides), whereas HAS1 (200-2000 kDa) and HAS3 (100-1000 kDa) produce shorter
dipeptide chains [61,68]. HASs are regulated by a number of mechanisms from temporal
expression patterns during development [69], to a wide range of cytokines and receptors [70]
and/or availability of substrates for HA synthesis [61].

HA Chain

Outside
Membrane

= UDP-GlcNAc

= UDP-GlcA

Figure 2.2. Addition of GlcNAc and GlcA by the HA transmembrane synthases

Over decades, there has been no consensus or clear nomenclature in regards to the
molecular weight categorization of HA. Cyphert and colleagues recently proposed the following
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designations: HMW-HA for >1000 kDa, low molecular weight HA (LMW-HA) for <1,000 kDa
to >20 monosaccharides, and HA oligosaccharides (oHA) for <20 monosaccharides in length [6].
Monslow and others (2015) categorized HA sizes more distinctly as HMW-HA (>1000 kDa),
medium molecular weight HA (MMW-HA) (250-1000 kDa), LMW-HA (10-250 kDa) and oHA
(<10 kDa) [5]. Monslow’s classification will be followed in this study. HA is usually found in
synovial fluid, vitreous humor and connective tissue. Sulfated GAGs are smaller than HA and their
size ranges from 4-70 kDa. CS has a molecular weight of 5-50 kDa and is found in cartilage,
tendon, ligaments and arteries. DS (15-40 kDa) is found in skin, blood vessels and heart valves
and KS (4-19 kDa) is found in the cornea and in cartilage aggregated with CS. HP (10-12 kDa) is
a naturally occurring anticoagulant stored in mast cell vesicles especially in the liver, lungs and
skin. HS (10-70 kDa) is ubiquitously expressed in animal cell surfaces [63,64,66].

2.3.3. Signaling and Biological Functions of Hyaluronan
Despite their simple chemical composition, GAGs fulfill several distinct molecular
functions. For many years HA was considered an inert filler in the ECM, however it is now known
that it possesses a plethora of often opposing size-dependent biological functions [71]. HA
contributes not only to the structural and physiological characteristics of tissues, but also mediates
cell behavior during morphogenesis, tissue remodeling, inflammation and diseases. As a signaling
molecule, HA interacts with a variety of cell surface receptors to activate intracellular events to
mediate cell functions [8]. HA is the main ligand to CD44, a receptor expressed on the surface of
almost all human cells involved in many cell-cell interactions and in a wide variety of cellular
functions [61,72]. A study by Teder and others suggests that CD44 plays a critical role in HA
clearance and homeostasis following lung injury which influences the recovery from pulmonary
inflammation. Moreover, they showed that mice accumulate LMW-HA following bleomycin
12

induced lung injury, however after inflammation is resolved, HMW-HA synthesis is predominant
[73]. LMW-HA levels in the bronchoalveolar lavage (BAL) of CD44-negative mice have been
reported to be 2-fold higher than wild type [74]. Jiang and others showed that HA fragments induce
pro-inflammatory macrophage inflammatory protein-2 (MIP-2), the murine equivalent to human
IL-8, and lung epithelial cell-specific overexpression of HMW-HA was protective against lung
injury [75]. Similarly, mice and macrophages exposed to HMW-HA prior to LPS injection had
greatly decreased interleukin-6 (IL-6) and TNF-α levels in serum and mRNA expression,
respectively. This effect was not observed in CD44-negative mice or macrophages [76]. HA can
also modulate key cancer cell functions through interaction with its CD44 and receptor for
hyaluronan mediated motility (RHAMM) receptors [77].

The interaction of HA with the RHAMM can also trigger several signaling cascades
including the NF-κβ pathway [61]. RHAMM is normally localized intracellularly and is only
released by some poorly defined stimuli. Extracellularly, RHAMM associates with CD44 and upon
binding with HA, it activates intracellular signaling pathways [8]. The interaction of RHAMM
with a oHA (6-mer) was shown to play an important role in the inflammatory and fibrotic processes
resulting from acute lung injury by bleomycin in mice [78]. A study using primary tracheal
epithelial cell cultures treated with HA (200 kDa) at 50 ug/mL proposed a model in which HA
serves a key role in mucosal host defense. HA, through its interaction with RHAMM, stimulated
ciliary beating and hence the clearance of foreign material from mucosal surfaces while still
regulating enzyme (lactoperoxidase and tissue kallikrein) homeostasis [79].
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Toll like receptors (TLRs) are able to rapidly initiate the innate immune response, which
represents the first defense against pathogens. The negative and positive effects of TLRs
interaction with LMW-HA and HMW-HA, respectively, have been previously reviewed [61]. In a
murine lung injury model, the knockout of TLR2 and TLR4 abolished completely the activation
of chemokines in macrophages. Moreover, oHA induced the nuclear translocation of NF-κβ and
production of TNF-α [75]. The expression of MMP-2 and IL-8 is also stimulated by HA fragments
in part by signaling of TLR4 [80]. On the other hand in human monocytes, HMW-HA via its
engagement with CD44 and TLR4 is a positive regulator of IL-1R-associated kinase-M (IRAK),
which is thought to be a negative regulator of inflammatory TLR signaling [81]. HA of different
sizes can also signal through the lymphatic vessel endothelial hyaluronan receptor 1 (LYVE 1)
and the hyaluronan receptor for endocytosis (HARE). HARE has a complex structure including
several HA and other GAG binding motifs. The binding of human or rat HARE with HA of an
optimum size of 140 kDa has been shown to stimulate the activation of NF-κβ [82]. In aggregate,
affinity for receptors, receptor clustering and uptake will differ depending on HA size, which may
affect downstream signaling cascades. Cell type may also be a driver of differences in HA
signaling.

Binding of HA with tumor necrosis factor-alpha stimulated gene-6 (TSG-6) is involved in
the mediation of lymphocyte migration during inflammation. This binding results in the formation
of fibrils that are pro-adhesive to lymphocytes which prevents direct contact of inflammation
promoting receptors and elastases with the underlying tissues [83–86] (Figure 2.3). HA cables
synthesized by mouse or human airway smooth muscle cells can also form independently without
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the presence of TSG-6. These cables are capable of binding a large number of leukocytes and can
sequester pro-inflammatory chemokines through interactions with CS and DS chains [87,88].

An investigation on airway responses in sheep showed that the preventive inhibitory effects
of inhaled HA (3, 6, 7 or 15 mg in 3 ml phosphate buffered saline (PBS)/ sheep) against human
NE-induced bronchoconstriction, could extend for at least 8 hours. Both LMW-HA and MMWHA showed a dose-dependent inhibition of the inflammatory responses, however above 150 kDa,
dose and not molecular weight was the key for effective protection [11]. It has been proposed that

Figure 2.3 Binding of HA to alveolar septal elastic fibers upon intratracheal
administration may prevent their degradation by elastases [86]

this protective effect of HA may be accompanied by an improvement in pulmonary mechanics due
to HA’s special ability to retain water which may help increase the elasticity of lung elastic fibers
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[12]. Furthermore, lipopolysaccharide-induced TNF-α, IL-6, and interleukin-1 beta (IL-1β) in
human macrophages have been dose-dependently suppressed by different doses of 2,700 kDa HA
(0.01, 0.1 and 1 mg/ml). HA (800 kDa) showed no significant effect even at 3 mg/ml. The same
study proposed injection of HA into arthritis joints as an anti NF-κβ agent [89].

Due to its biocompatibility, biodegradability, non-immunogenicity, water binding
properties and receptors (CD44, RHAMM, TSG-6, HARE, LYVE 1), HA has drawn attention in
the field of biopharmaceutics. HA-drug conjugates may be used to increase the solubility,
permeability and bioavailability of several anti-cancer and anti-inflammatory drugs [90].

Iovu and others have thoroughly reviewed the anti-inflammatory activity of CS in
osteoarthritis. CS and/or its disaccharides reduce inflammation (TNF-α, IL-1β, ROS and nitric
oxide) in joint chondrocytes and synovial membrane through the inhibition of NF-κβ nuclear
translocation [91]. The role of CS in synovial angiogenesis modulation has been suggested by
Lambert and others in a study using biopsies from normal and inflammatory osteoarthritic
membranes. Synovial biopsies from inflamed areas expressed pro-angiogenic phenotypes
promoted by IL-1β and CS (10, 50, 200 µg/ml) dose-dependently reversed this effect [92]. In a
psoriasis model using normal human keratinocytes, CS (200 or 1000 µg/ml) effectively
downregulated the NF-κβ and signal transducer and activator of transcription 3 (STAT3) pathways
[93]. These effects limited the release of key psoriatic pro-inflammatory cytokines such as TNFα, IL-8, IL-6 and the cutaneous T cell-attracting chemokine (CCL27). HA, CS and DS extracted
from fish have been shown to reduce gliadin-mediated inflammation, in a celiac disease model
using human Caco-2 cells, through a decrease in the production of IL-1β [94]. The biological
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functions of CS and DS have also been reviewed in the light of their structural interactions with
microbes, cell adhesion molecules and growth factors [95]. Octasaccharides of over-sulfated CS
can inhibit herpes simplex virus infections and a specific CS sequence has also been shown to be
a potential target for the treatment of malaria [96,97]. Highly sulfated CS and DS bind strongly
with key liver regeneration growth factors and therefore may be potential candidates for
development of therapeutics [95]. Tissue regeneration properties in the central nervous system
have also been attributed to CS disaccharides [98]. Regarding tumor growth, it has been shown in
vivo that cisplatin-CS liposomes are avidly internalized by highly metastatic liver cancer cells
which results in cell death [99]. It has also been reported that sulfated GAG-rich wound fluids
markedly inhibit the antibacterial action of the antibacterial peptide LL-37 through specific GAGLL-37 hydrophobic interactions and hydrogen bonding [100]. Finally, HA and the sulfated GAGs
might also be therapeutic agents in other diseases with strong inflammatory components such as
inflammatory bowel disease, atherosclerosis, Parkinson’s and Alzheimer’s diseases, multiple
sclerosis, lupus, rheumatoid arthritis and CF [10,101–103].

2.3.4. Degradation
The human body produces thousands of dollars’ worth of HA daily, however the action of
HAses and ROS with aging and during diseases make its abundance and molecular weight
decrease [2,3,9,104]. HAases were first termed as such in 1971 by Karl Meyer who also classified
them in three distinct types based on biochemical analyses and generated end products. The first
class constitutes a family of enzymes derived from animal venoms, urine, blood and sperm, among
others. They are responsible for the fragmentation of HA of all sizes into short chains, down to
tetra-saccharides. The second class of HAases has not been studied, however they are known as
the leech HAases due to their presence in blood sucking organisms like leeches, bed bugs, ticks,
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flies, mosquitoes and certain crustaceans. Microbial HAases are the third type and they decrease
the permeability of the ECM to facilitate invasion of pathogens and spreading of toxins. Fungal
HAases have not been characterized yet [67,105]. Higher levels of HAase expression and activity
have been documented in many diseases. A type 1 HAase has been shown to have an important
regulatory role in bladder cancer and increases in its relative abundance lead to increased tumor
growth and proliferation [106,107]. There have also been indications that HAases are involved in
the turnover of HA during early phases of lung injury and might play important roles in the
pathogenesis of lung fibrosis [108]. Acute exacerbations of chronic obstructive pulmonary disease
(COPD) are associated with increased HAase activity in BAL, which may contribute to airway
inflammation and lung function decline [109].

The molecular weight of HA may be altered by oxidative damage [110]. The size of HA in
cigarette smoke exposed mice is significantly smaller (70 kDa less in average) than HA of mice
not exposed to smoke [111]. Several previous studies have reported hydroxides as the primary and
sole species responsible for HA degradation [112–115]. Moreover, inhibition of ROS induced HA
degradation was linked to a reduction of inflammation in bleomycin and asbestos-induced models
of pulmonary fibrosis [116,117]. A murine model of allergic contact dermatitis demonstrated that
an increased production of ROS is accompanied by HA breakdown to pro-inflammatory LMW
fragments in the skin [118]. Other non-enzymatic reactions that may degrade HA (acidity,
alkalinity, ultrasound and heat) have been reviewed in detail by Stern and others [119].

2.3.5. Sources
GAGs have a great variety of structures and biochemical features which vary depending
on the source, type of tissue, age, physiological conditions and extraction methods, among others.
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This variability makes GAG chains or fragments versatile to interact with many kinds of receptors
and bioactive proteins. This heterogeneity however, complicates the reproducibility of yields and
clinical effects.

HMW-HA was extracted from fresh cattle vitreous humor in 1934 with a reported yield of
0.25 g from 100 eyes [65]. Currently, a well-established source of HA is chicken combs. Severo
da Rosa and others extracted 15 µg hexuronic acid/ mg dry tissue, which is equivalent to
approximately 2.4 µg hexuronic acid/ mg wet chicken combs. The extraction of the total GAGs
was conducted through acetone dehydration and choloroform: methanol delipidation followed by
papain digestion and precipitation by a series of NaCl and ethanol washes [120]. These results
from 42-day old animals are lower than the values reported by Nakano and others in rooster comb
(4.0 µg uronic acid/ mg wet tissue) from 52-week old animals following a method in which
samples were dehydrated with acetone prior to papain digestion, tricholoroacetic acid (TCA)
deproteinization and dialysis [121]. Higher HA content values in rooster combs were also reported
by Nakano and Sim in 1989 and the concentration was also estimated to be two-fold greater in the
comb than in the wattle [122]. HA was also extracted from rooster combs by Kang and others
using a method that aimed to reduce time and cost to accommodate a large-scale process. Frozen
comb samples (500 g) were ground and defatted/dehydrated with acetone to yield 80 g of dry
material that was extracted with sodium acetate and purified with ethanol followed by dialysis.
Finally, the HA was precipitated with ethanol and heat treated to yield 1 µg dry HA/ mg wet tissue
of an average molecular weight of 1200 kDa [123]. The rooster comb extraction process is facing
a growing concern over the use of animal derived components in biomedical and pharmaceutical
applications [33].
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Fish and fish eyeballs are also a valuable source of HA GAGs. Swordfish (Xiphias gladius)
and shark (Prionace sp.) vitreous humor was decomposed and clarified by centrifugation before
ultrafiltration, electrodeposition and alcoholic precipitation in a process optimized by Murado and
others. The reported yields were 0.055 and 0.3 g HA/ Kg of vitreous humor in swordfish and shark,
respectively. In the same study, HA concentrations for pig synovial fluid (0.5-6 g HA/ L) and pig
vitreous humor (0.04 g HA/ Kg) were reported [124]. GAGs have also been isolated from haddock
(Theragra chalcogramma) by papain digestion, TCA deproteinization, dialysis, and
cetylpyridinium chloride (CPC) precipitation. The Fourier transform infrared spectroscopy (FTIR) absorption spectra of the purified haddock extracts fitted the main characteristics of GAGs and
suggested the presence of CS and DS, but mainly HA [94]. Chicken (42 d old) keel cartilage has
been reported to be a good source of CS following extraction with magnesium chloride. Results
showed a yield of 33 mg GAGs/ g wet keel cartilage and 75.5% of the GAGs were CS with an
average molecular weight of 48.5 kDa [125].

Despite the abundance of animal sources of HA, currently the main production method is
microbial fermentation due to lower costs and environmental impact. Microbial HA production on
an industrial scale was first achieved by Shiseido Group (Tokyo, Japan) in the 1980’s and since
then significant advances have been made to increase fermentation efficiency. Culture conditions
(pH, temperature, culture media, agitation speed, shear stress, dissolved oxygen, bioreactor type)
and batch modes (batch vs continuous) have been extensively studied to increase HA yields instead
of promoting cell growth. Streptococcus sp. is the main producer, however the industry is facing
issues due to its pathogenicity [33,104]. Recently, the production of HA by Streptococcus equi
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subsp zooepidemicus in media formulated from fish by-products was investigated. The process
yielded more than 2 g HA per liter with a molecular weight of 1730-1900 kDa and remarkable cost
savings (>50% less than commercial media) [126]. Similarly, the yield of HA from the same
bacterial strain using commercial media was 2.83 g/L with a protein content of 23.08% and average
molecular weight of 538 kDa. The FT-IR spectrum showed the characteristic stretches of HA
standards and excellent wound healing properties in a rat model [127].

Addressing the drawbacks of bacterial fermentation and animal sources, Novozymes
(Copenhagen, Denmark) recently launched HA production by Bacillus subtilis using a water based
process and a growth medium free of animal ingredients or toxins. Moreover, defined molecular
weights can be produced [128]. Other bacteria used for recombinant HA production include
Lactococcus lactis [129], Agrobacterium sp. [130], and E. coli [131] with yields of 0.65, 0.3 and
2.0-3.8 g/L, respectively. Recombinant HA production yields are generally lower than bacterial
fermentation yields.

2.4.

Cystic Fibrosis

2.4.1. Introduction
CF is a life-limiting condition that affects ~29,000 individuals in the United States and
~70,000 worldwide with an estimated frequency of 1 in 2,500 births [30,132,133]. The disease
affects primarily those of European descent, however it has been reported in all races and
ethnicities [15]. It is an autosomal recessive disorder specifically related to abnormalities in the
expression and function of the CFTR resulting in abnormal ion transport across epithelial surfaces
in the sweat glands, gastrointestinal, reproductive and respiratory systems. The abnormal salt and
water transport results in viscous secretions in the airways of the lungs and pancreas ducts, leading
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to obstructions that cause inflammation, tissue damage and finally failure of the organ systems
[15,134]. Achieving and maintaining an optimal nutrition status is a critical component of CF care
[135], however obstructive lung disease is the primary cause of morbidity and is responsible for
~80% of the mortality [15]. The median survival age has increased significantly from 33.4 years
in 2003 to 40.7 years in 2013 [136] due to currently available therapies that address the CFTR
defect consequences (pancreatic enzyme supplements, antibiotics, anti-inflammatory drugs and
sputum thinners) or the CFTR basic defect (CFTR potentiators) [134,137].

2.4.2. History of Cystic Fibrosis
The first description of this disease in the United States was published by Dorothy
Andersen, M.D. in 1938 as a pancreatic affection, however it was until 1951 that a connection was
made between CF of the pancreas and widespread abnormality in epithelial salt transport [134]. In
1953, Sant’Agnese and colleagues reported that Na+ and Cl- levels were markedly elevated in the
sweat of CF patients and pointed towards a disturbance in the sweat glands [138], leading to the
development of the sweat test as a reliable diagnostic test for CF in 1959 [139,140]. In the 1980’s,
a number of studies supported the hypothesis that the disease’s basic defect altered Cl- permeability
[141–143] and in 1989 the gene responsible for CF was cloned and called CFTR [144,145]. In the
clinics, major advances in treating the symptoms and delaying disease progression have been made
over the years, hence improving quality of life and increasing life expectancy. This is a result of a
better understanding of the natural course of inflammation and infection which has resulted in
strategies to assure prompt diagnosis, timely nutritional supplementation, early treatment of
exacerbations and implementation of effective hygienic measures in and outside CF centers,
among others [146].
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2.4.3. The Cystic Fibrosis Transmembrane Conductance Regulator Protein
CFTR is a member of the adenosine triphosphate (ATP)-binding cassette family of
transporters, which use energy from ATP hydrolysis to pump substrates across cellular
membranes. It is the major epithelial ion (Cl-) regulator located primarily in the apical plasma
membrane, therefore it is key in transepithelial salt transport and fluid flow [137,147]. The amino
acids of CFTR form five domains: two membrane spanning domains (MSD-1 & MSD-2), two
nucleotide binding domains (NBD-1 & NBD-2) and a regulatory domain (RD). The opening of
the anion pathway in CFTR requires phosphorylation of the channel by cyclic adenosine
monophosphate-dependent protein kinase A (cAMP-PKA). Once the CTFR RD is phosphorylated,
channel gating is regulated by ATP hydrolysis in the NBDs. The RD is dephosphorylated by
protein phosphatases to return the channel to its inactive state (Figure 2.4) [134,139,147].

Figure 2.4. Model showing the proposed domain structure of the CFTR [147].

23

In addition to regulation of CTR function by nucleotide binding and phosphorylation, the amount
and quality of CFTR production are also tightly regulated in the endoplasmic reticulum [148].

The CFTR is directly responsible for CF and a person must have two abnormal CFTR
genes

to

manifest

the

disease.

According

to

the

CFTR

Mutation

Database

(http://www.genet.sickkids.on.ca/), there are six classes of CFTR mutations which include 2,006
different mutations [149] that result in a particular phenotype (Figure 2.5).

Figure 2.5. Classification of CFTR mutations [150].

The F508del mutation is associated with severe CF and it is the most common mutation
occurring in ~86.4% of patients in one or both alleles. This is a class II mutation in which the
CFTR protein is created but misfolded, keeping it from reaching the cell surface, specifically due
to a phenylalanine residue deletion in the 508 position [145]. Other CFTR mutation classes include
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nonsense mutations (Class I), altered gating mutations despite expression of full length protein
(Class III), misense mutations resulting in lowered Cl- permeability (Class IV), insufficient
synthesis of CFTR (Class V) and reduced CFTR half-life in the apical membrane mutations (Class
VI) [133,134,150]. These dysfunctions in the CFTR disrupt ion transport in the epithelia of various
organs which results in the many manifestations of the disease, from airway disease and pancreatic
failure to male infertility and elevated electrolyte levels in sweat [138,151–153].

In addition to its role in Cl- transport, the CFTR in its active state negatively regulates the
epithelial Na+ channel (ENaC). Since Cl- conductance is defective in CF, ENaC currents are not
inhibited resulting in increased Na+ absorption in the airway epithelium and depletion of the airway
surface liquid (ASL) which is known as the “low-volume hypothesis” [154–157] (Figure 2.6).

Figure 2.6. Low volume hypothesis for CF [158].
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2.4.4. Diagnosis
Nationwide newborn screening for CF has been in place since 2010 and even earlier in
some states. As a result, a growing proportion of people are now diagnosed in infancy and in 2014,
63.7% of new diagnoses were detected within the first year of life and often before the onset of
symptoms [133,136]. There is consensus that CF is diagnosed based on evidence of CFTR
abnormality (sweat test or genotyping) and characteristic phenotypic features or family history.
There has been a decrease in the use of sweat electrolyte testing due to an increased reliance on
genetic testing, however the challenges of using genetic analysis alone are that it does not provide
information about the gene product or function and all of the mutations might not be identified
[139,159,160]. Early diagnosis and treatment have led to better lung function and nutritional
outcomes later in life, however the disease continues to be characterized by a number of life
threatening symptoms.

2.4.5. Airway Pathophysiology in Cystic Fibrosis
Abnormal CFTR expression in the human bronchus affects predominantly the submucosal
glands. [161,162]. Clinicians often describe CF as a vicious cycle of airway inflammation,
obstruction and infection in which each of these components contributes to the progression of the
lung disease [163]. The main cause of death is due to chronic inflammation and persistent
infections with Pseudomonas aeruginosa and other pathogens. This section focuses only on the
pulmonary aspects of this genetic disease and does not include other important aspects of this
illness including gastrointestinal, endocrine and metabolic manifestations.

CF leads to severe pathological changes in the airway epithelium as it induces an early,
intense and constitutive inflammatory process even before the onset of bacterial infection [21].
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This congenital pro-inflammatory phenotype is caused by an innate increase in ROS promoted by
misfolded protein stress and TGAse-driven defective autophagy of misfolded or damaged CFTR
aggresomes [164–166]. It has also been demonstrated in human CF epithelial cell lines and in adult
CF mice (F508del) that TGAse is a driver of inflammation in CF airways and it can be upregulated
by ROS [29]. This inflammatory process leads to the increased expression of NF-κβ and proinflammatory cytokines as well as a large recruitment of neutrophils [17–20]. Moreover, the
excessive production of the serine protease NE, overwhelms the normal anti-proteinase capacity
and results in irreversible airway structural damage which overwhelms the normal repair pathways
[167,168]. Although NE’s physiological role is to degrade phagocytosed proteins, it also degrades
structural proteins like elastin, collagen, fibronectin and proteoglycans causing damage to the
airway epithelia [169,170] and contributing to bronchiectasis progression. NE is also the most
significant predictor of bronchiectasis in early-life CF [171]. It has been reported that neutrophils
from CF patients release significantly more ROS that neutrophils from healthy individuals [172],
thus further perpetuating the inflammatory response. Furthermore, the lysis of neutrophils results
in large amounts of DNA that contribute to the increased viscosity and adhesiveness of lung
secretions and formation of mucous plugs [173].

The airway tissue damage and the ion transport defects in CF epithelia cause deficiencies
in mucociliary clearance (MCC) that result in airway obstruction. Sodium hyper-absorption and
defective chloride secretion drive increased water absorption by osmosis which reduces mucus
clearance and increases mucus adherence resulting in a reduced ASL height [158]. The ASL
consists of two layers above the epithelial surface: a mucus layer and a perciliary liquid layer [174]
and it has been suggested in mouse, human and in vitro studies that its hydration status predicts

27

the outcome of therapeutic interventions [156,175,176]. Understanding of this pathological
condition is critical as MCC is recognized as the primary physiologic defense mechanism and it is
used as an outcome measure in the development of new physical and pharmacological therapies
for patients with CF. Moreover, for normal MCC to occur it is necessary that the airway epithelial
cells are intact [177] and as discussed previously this is compromised in CF airways due to the
exaggerated expression of NE. It has been demonstrated in vitro that mucus transport is lost within
24 h in CF cultures, compared to up to 72 h in normal airways, mainly as a result of increased
absorption of liquid from the culture surface [178]. A study in mice with airway-specific
overexpression of ENaC, demonstrated that the lungs are normal at birth, however there is an early
surface dehydration, increased mucus concentration and increased mucus adhesion that produce
mucus plugging which triggers airway inflammation and is associated with early mortality [179].
In humans, large volumes of viscous mucopurulent sputum are accumulated putting patients at a
higher risk of developing lung infections [180]. A long term clinical study measured a significant
reduction in pulmonary exacerbations, compared to a control group, upon the administration of
hypertonic saline solution twice daily during 48 weeks (4 ml of 7% saline) [181]. Likewise,
Donaldson and others reported an improvement in MCC after a 14-day saline treatment (5 ml of
7% saline) four times daily. Despite improvement in treatments, decreased lung function and
COPD have been and continue to be the leading cause of CF morbidity and mortality [182–184].

Along with obstructive pulmonary disease, chronic infections represent a serious problem
for most individuals with CF and it is considered a paradox that the large numbers of neutrophils
present in the CF airways fail to effectively kill colonizing bacteria [167]. Bactericidal activity has
been reported in CF epithelia at low NaCl concentrations, however the CF ASL has a high NaCl
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concentration which reduces bactericidal activity [151]. More recently, Pezzulo and others (2012)
showed that the lack of CFTR reduces bacterial killing in newborn pigs and in primary epithelial
cultures. This result was linked to a lower ASL pH in CF pigs compared to their wild-type
counterparts and further linked to a HCO3- transport deficiency. CFTR facilitates HCO3- secretion,
therefore its absence or malfunction causes the ASL pH to fall which inhibits antimicrobial
function, reduces MCC and finally facilitates bacterial colonization [185,186]. Similarly, Nordin
and others (2013) investigated the expression pattern and activity of the antibacterial growth factor
midkine in CF lung tissue. Midkine was present at 100-fold higher levels in CF sputum when
compared with sputum from healthy control subjects, however it was subject to increased
degradation into smaller fractions by NE which impaired its bactericidal properties against P.
aeruginosa. Increased salt and acidity also impaired its bactericidal properties in vitro [187].

Bacterial infections in CF frequently have an age-dependent sequence (Figure 2.7). In
2014, the CF Foundation reported that early infections are most frequently caused by
Staphylococcus aureus, P. aeruginosa and Haemophilus influenzae, however P. aeruginosa is by
far the most significant pathogen throughout the life of CF patients [133,188]. There is evidence
indicating that in young children with CF, early P. aeruginosa infection gradually declines lung
function and increases the risk of morbidity and mortality [189,190]. Additionally, Aaron and
others (2015) constructed a statistical model to assess the 1-year risk of death for CF patients using
data from 1970 up to 2010 and concluded that having Pseudomonas plays a critical role especially
when a patient’s overall health is moderately to severely compromised [191]. Even though the
prevalence of P. aeruginosa continues to decrease due to prevention of initial infection, there is
still a prevalence of multi-drug resistant P. aeruginosa (18.1% of CF patients in 2014). A five-fold
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increase in prevalence of methicillin resistant S. aureus has also been reported which becomes
critical as S. aureus isolation has been proposed as a risk factor for initial P. aeruginosa infection
in young CF patients [192].

Figure 2.7. Prevalence of Respiratory Microorganisms by Age Cohort, 2014 [133].

In CF patients P. aeruginosa has demonstrated a very high level of adaptation and
mutability to establish a persistent infection, likely caused by the large diversity of infecting
organisms, ineffective host defenses and ongoing antibiotic therapies [188,193,194]. Among the
organisms identified later in the course of CF disease are: the Burkholderia cepacia complex,
Strenotrophomonas maltophilia, Achromobacter, Aspergillus and other non-tuberculous
mycobacteria [195–200]. Of these, the B. cepacia complex is the most dangerous because of its
rapid progression to death through high fevers and bacteremia [188].

2.4.6. Current Treatment
Current CF clinical practice guidelines recommend individuals ages 6 and older to visit
care centers at least four times per year to conduct microbiological cultures, perform pulmonary
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function tests, receive an influenza vaccine, measure liver enzyme levels and blood levels of fatsoluble vitamins [136]. CF is a disease that requires more intensive treatments as the disease
progresses, therefore the availability of multiple pulmonary therapies is beneficial. Typically,
chronic pulmonary therapies with dornase alfa, hypertonic saline, ibuprofen and/or tobramycin,
among others, are a major component of the treatment regime [133,201,202] (Figure 2.8). DeWitt
and others (2008) estimated the United States mean annual cost of care for patients with CF with
mild impairment in lung function to be over $43,000. These costs are driven by medications, but
also include hospitalization costs, emergency room and home nursing visits and indirect costs
associated with missed school or work days [203]. More recently, similar costs (€26,335 - €76,271)
were reported for patients in the United Kingdom depending on the severity of the disease [204].

Figure 2.8. Chronic Medication Use in CF Patients, 1995-2014 [133].

Dornase alpha is an orphan drug described as a recombinant human deoxyribonuclease
(DNase) that hydrolyzes DNA present in the sputum of CF patients, reducing the lung viscosity
and improving MCC [205,206]. The nebulized use of this DNase is prescribed for the majority of
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the population and more than half is prescribed hypertonic saline either in place of, or in addition
to dornase alpha [133]. In a multicenter study of 48 CF patients, 18 months treatment (2.5 mg/day)
with dornase alpha reduced DNA load in BAL [207]. A 3-year multicenter study with 105 patients
reported on the positive influence of dornase alpha on airway inflammation. It was shown that
neutrophil content, NE activity and IL-8 remained stable in patients treated with DNase compared
to control and untreated subjects [208]. Two week dornase alpha treatment has also been shown
to improve forced expiratory volume in 1 second (FEV1) in 67% of patients independently of
weight, age or baseline FEV1 [205]. More recently, it was reported that DNase treatment (25 µl of
1 mg/ml) in mice eliminates lung neutrophil extracellular traps and improves lung mechanics,
however it does not prevent airway inflammation [209].

Hypertonic saline (HTS) is also available to CF patients as a means to restore ASL. HTS
is defined as a solution possessing an osmotic pressure greater than that of physiologic isotonic
NaCl solution (0.9%) and popularity of its use has increased on the basis of a number of studies
[210]. Inhalation of HTS has been reported to increase airway antioxidant levels, improve MCC,
increase ASL hydration, and inhibit ENaC, among other positive effects. In a study on adult CFTR
knockout mice, nebulized 7% sterile HTS (2 mL/mouse) promoted an increase in glutathione, an
airway antioxidant that can protect the airways from hypochlorous acid mediated injury [211]. A
long term (48 weeks) clinical study with 164 CF patients showed that patients treated with 7%
HTS (4 ml twice daily) had significantly higher forced vital capacity (FVC) and FEV 1, as well as
fewer pulmonary exacerbations than control patients. Furthermore, significant improvements in
quality of life were observed [181]. HTS at a concentration of 3% or higher is used to create an
osmotic gradient that draws water into the airway surface, therefore improving ASL and
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facilitating MCC [212]. The findings of a human study by Hebestreit and others indicate a
significant inhibition of luminal sodium conductance by HTS which may be associated with
improved fluid transport across the respiratory epithelium, improved MCC and increased lung
function [213]. There is also increasing evidence suggesting that HTS is beneficial through its antiinflammatory properties due to reduction of IL-8 concentrations and neutrophil chemotaxis in CF
airways [210]. Moreover, HTS has the ability to reduce bacterial activity and biofilm formation
[214,215]. Finally, the tolerability and pleasantness of 7% HTS can be significantly improved
when administered together with 0.1% HA, thus improving adherence to HTS therapy due to
reduced cough, throat irritation and saltiness [24,32].

Symptomatic therapies to treat CF patients include non-chronic use of high-dose ibuprofen
(25-30 mg/kg) [133,216]. Ibuprofen administered twice daily for four years (50-100 µg/ml in
plasma) to CF patients (5-39 years old) with mild lung disease resulted in a slower annual rate of
change in FEV1 compared to patients assigned to placebo [217]. Similarly, a long term clinical
study with children and adolescents with CF concluded that ibuprofen treatment significantly
slowed the rates of FEV1 decline compared to untreated subjects [218]. In both studies the side
effects were not serious or the apparent benefits of ibuprofen therapy outweighed the small risks.
Despite its apparent benefits, ibuprofen is infrequently used due to the need to measure plasma
levels and because of the potential renal and gastrointestinal side effects [146].

Anti-infective pulmonary therapies with inhaled tobramycin, inhaled aztreonam or
azithromycin are also widely used in 69.8%, 42.5% and 67.5%, respectively, of CF patients (≥ 6
years) infected with P. aeruginosa [133]. Tobramycin is the established standard of antibiotic care
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in CF. It is an aminoglycoside antibiotic that has shown a sustained improvement in FEV1 upon
chronic inhaled administration over 2 years [219]. In a multicenter study of 520 patients,
intermittent administration of inhaled tobramycin for 6 months showed significant improvement
in lung function after two weeks and the effects were maintained throughout the study [220].
Tobramycin exerts its antimicrobial activity by binding to the bacterial ribosome and inhibiting
protein synthesis, thus inhibiting growth and division of the bacteria [221]. A recent study showed
that the combination therapy of HA plus tobramycin is effective in the treatment of bacterial
rhinosinusitis in CF [31]. Long-term treatment with azithromycin is also included in the current
guidelines for CF patients older than 6 years. Although it is not active against P. aeruginosa,
azithromycin can interfere in some bacterial activities and make them more susceptible to
antibiotic treatment [222]. Aztreonam was recently approved (2010) for the treatment of CF and
an aztreonam vs tobramycin comparative study demonstrated that aztreonam patients had fewer
respiratory hospitalizations [223]. Early anti P. aeruginosa antibiotics have been demonstrated to
successfully prevent chronic infection and improve clinical outcomes, however there is still debate
on the side effects of long term treatment, most importantly the development of antibiotic
resistance in airway pathogens.

GAGs have been investigated as potential molecules for the treatment of CF and airway
disease symptoms due to their water-retaining, re-epithelizing and anti-inflammatory properties,
among others. Nebulized 300-500 kDa HA (0.5 mg HA/animal/day for 7 days) was effective in
controlling inflammation in vivo in mice CF airways as well as in vitro in human airway epithelial
cells (100 µg HA/ml for 24 h) [10]. Adult sheep treated with nebulized 150 kDa or 300 kDa HA
(3-15 mg/ewe), dose dependently improved their pulmonary resistance after challenge with human
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NE [11]. Moreover, seven days after treatment of cultured ovine tracheal cells with HA, ciliary
beat frequency increased by 16% which may be indicative of the late expression of an HA-binding
receptor in this particular culture [224]. Researchers have also proposed the pivotal role of HA in
mucosal host defense by stimulating ciliary beating through its interaction with ciliary RHAMM
[79]. Finally, intranasal use of sodium hyaluronate (9 mg twice daily for 30 days) in patients
undergoing functional endoscopic sinus surgery for nasal polyposis significantly improved MCC
and other important clinical parameters [225].

The anti-inflammatory and tissue regeneration properties of sulfated GAGs have been
reviewed in various diseases, however the results have not been promising in relation to
symptomatic treatment of CF. For example, a pilot clinical study demonstrated no evidence of
improved FEV1, MCC or inflammation markers with a dose of 50,000 IU of heparin twice daily
for two weeks [226]. Furthermore, it has been shown that high expression of CS and HS in normal
and CF human lung tissue, facilitate the binding of IL-8 protecting it from proteolysis and
prolonging its activity [227,228].

2.4.7. Markers of Inflammation in Cystic Fibrosis
Dysregulated inflammation is an early event in CF and it has a direct link to defective
CFTR. The CFTR mutations lead to an increase in TGAse levels and activity which result in the
cross-linking and proteasome degradation of the peroxisome proliferator-activated receptor(PPAR), a key negative regulator of inflammatory gene expression [30]. This defect perturbs
the regulation of the NF-κβ pathway causing excessive production of inflammatory mediators
[229]. It has also been shown that the most characteristic feature of airway inflammation in CF is
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a persistent influx of neutrophils and an increased NE burden, driven by host and bacterial chemoattractants [16,230]. IL-8 is the major neutrophil chemo-attractant and its levels are elevated in the
BAL, sputum and serum of CF patients [231–233]. In healthy tissues, IL-8 is barely detectable,
but it is rapidly increased in response to pro-inflammatory cytokines, P. aeruginosa or cellular
stress [234,235]. Increased concentrations of other pro-inflammatory cytokines, such as IL-1β,
TNF-α and IL-6 have also been detected in CF airways [236–238]. Furthermore, the high NE load
in CF airways has been hypothesized to trigger the senescence of epithelial cells which can be in
a pro-inflammatory state. Three different senescence biomarkers were shown to be increased in
CF airways compared to control subjects, therefore contributing to the perpetuation of chronic
inflammation [239]. Most research focuses on increased activation of inflammatory responses,
however there is also an inability to resolve inflammation due to deficiencies in the expression of
anti-inflammatory molecules including interleukin-10 (IL-10), nitric oxide and lipoin-A4 [240].
IL-10 is not thought to be under direct control of NF-kB, however it terminates acute inflammatory
responses, downregulates production of TNF-α, IL-6, IL-1β and IL-8 by macrophages, inhibits
pro-inflammatory transcription factors and induces neutrophil apoptosis [236,240,241].
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CHAPTER 3
MATERIALS AND METHODS

3.1.

Experimental Design and Statistical Analysis
A completely randomized block design (CRBD), with three GAG extractions (repetitions)

as the blocking units, was used to test equality of means among treatments. The null (Ho: µ1 = µ2
= µ3 = µ4) and alternate (Ha: some µi is different) hypotheses were stated and all experiments and
analyses were conducted in triplicates. Analyses of variance (ANOVA) using Proc GLM were
conducted along with post-ANOVA Tukey pairwise tests using the Statistical Analysis System
(SAS®) version 9.4 Results were reported as means ± standard deviations (SD) and differences
were considered significant at p≤0.05.

The gene expression analysis experiments were carried out in triplicate and statistical
analysis was performed using the SABiosciences PCR Array Data Analysis Web-based software
which calculated fold-regulation p-values using a Student’s t-test on the fold-change values for
each gene in the treatment group compared to the control group (p≤0.05). ANOVA and postANOVA Tukey pairwise tests using the Statistical Analysis System (SAS®) version 9.4 were
conducted to evaluate RNA purity and PCR control gene expression. Results are presented as
means ± standard error (SE) (p≤0.05).

3.2.

Materials
Butyl alcohol (Cat. No. W217820), 2-mercaptoethanol (Cat. No. M-7154), absolute etanol

for molecular biology (Cat. No. E7023), porcine pepsin (Cat. No. P7125), L-cysteine (Cat. No.
W326305), ethylenediaminetetraacetic acid (EDTA) (Cat. No. E9884), sodium chloride (Cat. No.
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793566), crystalline carbazole (Cat. No. C5132), sodium tetraborate decahydrate (Cat. No.
B9876), HAase type 1 from bovine testes (607 U/mg) (Cat. No. H3506), ChrAse ABC from
Proteus vulgaris (Cat. No. C3667), CS-A from bovine trachea (Cat. No. C9819), Stains-All 95%
(Cat. No. E9379), gel loading buffer (Cat. No. G2526), single use micro DispoDialyzers™ (50
kDa molecular weight cut-off (MWCO)) (Cat. No. D9187) and dialysis cellulose tubing (14 kDa
MWCO) (Cat. No. D9402) were purchased from Sigma Aldrich (St. Louis, MO). Absolute ethanol
200 proof (Cat. No. 111000200) was purchased from VWR (Radnor, PA). Sodium hydroxide (Cat.
No. S318-3), acetic acid (Cat. No. UN2789), urea peroxide (Cat. No. ACS241020010), EMD
Millipore ACS grade sulfuric acid (Cat. No. MSX1244PC5), hydrochloric acid (HCl) ACS grade
(Cat. No. S25838), monobasic anhydrous sodium acetate (Cat. No. BP3331), Invitrogen™
Novex™ sharp pre-stained protein standard (Cat. No. LC5800) and HA standard from
Streptococcus sp. (94%) (Cat. No. AC251770010) were obtained from Fisher Scientific
(Pittsburgh, PA). Papain (Cat. No. 102566) was acquired from MP Biomedicals (Santa Ana, CA).
UltraPure™ agarose (Cat. No. 16500500) and tris borate-EDTA (TBE) buffer (Cat. No. 15581044)
were obtained from Thermo Fisher Scientific (Waltham, MA). Select-HA™ low polydispersity
HA standards HiLadder (1648, 1138, 940, 667, 509 kDa) and LoLadder (509, 310, 213, 111, 30.2)
(Cat. No. HYA-HILAD-20 and HYA-LOLAD-20) were purchased from Hyalose (Oklahoma City,
OK). Bovine serum albumin (BSA) (Cat. No. SC-2323) was purchased from Santa Cruz
Biotechnologies Inc. (Dallas, TX). Sodium phosphate (Cat. No. 0571), sucrose (Cat. No. 0335),
and ultrapure grade Tris-HCl (Cat. No. 0234) from Amresco (Solon, OH).

For the CF ex-vivo mice study retinoic acid (Cat. No. R2625), insulin (Cat. No. 91077c),
transferrin (Cat. No. T8158), cholera toxin (Cat. No. C8052), bovine pituitary extract (Cat. No.
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P1476), pronase from Streptomyces griseus (Cat. No. 10165921001) and DNase 1 from bovine
pancreas (Cat. No. DN25) were purchased from Sigma Aldrich (St. Louis, MO). Corning™ NuSerum growth medium supplement (Cat. No. CB-51000), Y-27632 ROCK inhibitor (Cat. No.
BDB562822), rat tail collagen I (Cat. No. CB-354249), Corning™ fetal bovine serum (FBS) (Cat.
No. 11648647), methyl sulfoxide (>99.8%) (Cat. No. AC327182500), phosphate buffered saline
solution (pH 7.4) (Cat. No. 10010031), recombinant mouse epidermal growth factor (Cat. No.
PMG8041), Dulbecco’s Modified Eagle Medium (DMEM)/Ham’s F-12 (1:1) (HEPES) (Cat. No.
11330-032), Gibco™ penicillin-streptomycin (10,000 U/ml; 10,000 mg/ml) (Cat. No.15-140-122),
Corning™ Primaria™ tissue culture dishes (Cat. No. 08-772-4A), Corning™ Costar™ Transwell™
clear polyester membrane inserts for 12-well plates (Cat. No. 07-200-161) and Falcon™ 6-well
tissue culture plates (Cat. No. 0877233) were obtained from Fisher Scientific (Pittsburgh, PA).

3.3.

Extraction of GAGs from Alligator Carcasses, Feet and Backstraps
Farmed AFT (2 anterior & 2 posterior) and ABS were collected from Vermilion Gator

Farm Inc. in Abbeville, Louisiana and waste ACS were provided by Jacques’ Croc’s and Farm
Pride (Scott, LA). All animals were between 12 and 18 months old at the time of slaughter and
samples were kept at -20◦C until used for GAG extraction at the Louisiana State University School
of Nutrition and Food Science (Baton Rouge, LA).

A Baader® 693 bone separator (Indianola, MS) was used to process ACS and separate
bones from meat. Three passes through a perforated stainless steel drum (Ø = 3 mm) were
performed at increasing belt pressures (20, 30 and 40 bar). Only bones including connective tissue
were used for GAG extraction from ACS. AFT and ABS were ground in a Hobart HCM450
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grinder-mixer (Troy, OH) prior to GAG extraction. The extraction process (Figure 3.1) was
developed by adapting methods previously reported by Ogawa and others [242], Losso and others
[243], Kittiphattanabawon and others [244], Severo da Rosa and others [120] and
Garnjanagoonchorn and others [245]. To remove non-collagenous proteins and bleach skin
pigments, the ACS, AFT or ABS were mixed with 0.2N NaOH at a sample: solution ratio of 1: 2.5
(w/v), in addition to 0.5% (w/w) urea peroxide. The mixture was stirred intermittently for 12 h
with a solution change after 6 h. The deproteinized samples were defatted with 20% butyl alcohol
(1:2.5 w/v) for 3 h and for removal of inorganic compounds samples were soaked in a 0.2N HCl
solution (1:2.5 w/v) for 3 h with manual stirring once every hour. Samples were filtered through
cheese cloth and washed in running tap water after every step. For collagen proteolysis, the
deproteinized, defatted and demineralized samples were finely ground with 1M acetic acid (1:2
w/v) and mixed with pepsin (0.3% w/w). Pepsin proteolysis was conducted for 4 h at 40°C,
followed by addition of papain (0.3% w/w) for 12 h at 60°C. Prior to use, papain was activated in
1:1 (w/v) digestion buffer (100 mM Na acetate, 5 mM L-cysteine, 5 mM EDTA). A double layer
of cheesecloth was used to filter the resulting clear solution and the filtrate was collected,
centrifuged (7,000 rpm/ 20 min/ 20°C) and filtered again using filter paper (Whatman No. 4).
Samples were dialyzed at 4°C using a 14 kDa MWCO cellulose membrane against distilled water
for 24 h, with solution changes every 8 h. The dialyzed samples were mixed (1:1 v/v) with a
solution composed of 2M NaCl: absolute ethanol (5:1). Absolute ethanol was added (1:2 v/v) and
GAGs were precipitated for 12 h at -20°C. The pellet was dissolved in distilled water prior to a
heat treatment (90°C/ 5 min) to inactivate enzymes and disinfect samples. Finally, samples were
centrifuged to discard the pellet and collect the supernatants which were freeze dried in a VirTis
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Filtration
(No. 4 Filter Paper)

Preparation of Materials for
Extraction (Desinewing or
Grinding)

Dialysis (24 h @ 4◦C)
(Distilled Water/ 3 changes)

Bleaching & Myofibrillar Protein
Removal (12 h)
(0.5% w/w Urea Peroxide &
0.2N NaOH @ 1:2.5 w/v)

NaCl Addition (1:1 v/v)
(5:1 2M NaCl: A. Ethanol)

GAG Precipitation
(12 h @ -20◦C)
(1:2 v/v Absolute Ethanol)

Defatting (3 h)
(20% Butanol @ 1:2.5 w/v)

Demineralization (3 h)
(0.2N HCl 1:2.5 w/v)

Sediment Dissolution
(Distilled Water)

Collagenous Protein Digestion
(4 h @ 40◦C)
(1M Acetic Acid @ 1:2 w/v &
0.3% w/w Pepsin)
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(90◦C / 5 min)

Centrifugation
(7,000 rpm / 20◦C / 20 min)

Papain Proteolysis
(12 h @ 60◦C in 1:1 w/v digestion
buffer)
(0.3% w/w Papain)

Supernatant Freeze Drying

Filtration
(Cheesecloth)
GAGs Storage at -80◦C
Centrifugation
(7,000 rpm /20◦C / 20 min)

Figure 3.1. Process diagram of GAG extraction from alligator ACS, AFT and ABS.
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Genesis 35XL pilot lyophilizer (Stone Ridge, NY) during 24 hours. Dry samples (< 5.0%
moisture content) were stored at -80°C until analyzed.

3.4.

Extraction of GAGs from Alligator Eyeballs
Farmed AEB were manually collected from heads at Vermilion Gator Farm Inc. in

Abbeville, Louisiana. Alligator eyeball GAGs were obtained as reported by Murado and others
with modifications [124]. AEB were cut vertically in half using a sharp scalpel blade to extract the
vitreous humor (Figure 3.2). Subsequently, the vitreous humor was dissolved in distilled water
(1:1 v/v) and homogenized in order to deconstruct it. Subsequently, the humor was clarified by
centrifugation at 7,000 rpm (20 min / 4 °C). Two clear phases were obtained: dark sediment of
impurities and a majority of vitreous humor supernatant. The supernatant was collected and protein

Papain Proteolysis of Supernatant
(1 h @ 60◦C in 1:0.1 w/v digestion
buffer)
(0.1% w/v)

Collection of AEB

Extraction of Vitreous Humor

Dialysis (24 h @ 4◦C)
(Distilled Water/ 3 changes)

Deconstruction and Homogenization of
Vitreous Humor
(Distilled Water 1:1 v/v)

Heat Treatment
(90◦C / 5 min)

Centrifugation
(7,000 rpm /4◦C / 20 min)

GAGs Storage at -80◦C

Figure 3.2 Process diagram of GAG extraction from AEB.

42

hydrolyzed using papain in digestion buffer as described previously. Samples were dialyzed at 4°C
using a 14 kDa MWCO membrane against distilled water for 24 h, with solution changes every 8
h. Finally, the samples were heat-treated (90 °C/ 5 min) and stored at -80°C until used.

3.5.

Determination of Sulfated GAGs, HA and Total GAGs Content
The content of sulfated GAGs was determined using a Chondrex Inc. (Redmond, WA)

dimethylmethylene blue (DMB) assay (Cat. No. 6022) as reported by Garnjanagoonchorn and
others [245]. Calibration curves were developed using a chondroitin-6-sulfate standard and
samples were solubilized and diluted with PBS to fit the standard range. One hundred microliters
of standards, samples and sample blanks were added in triplicates to a 96-well plate. Subsequently,
a 1,9-DMB solution (100 µl) was added into the standard and sample wells, while PBS (100 µl)
was added into the sample blanks. The plate absorbance was read at 525 nm within 5 min of DMB
addition in a Bio-Rad Benchmark Plus Microplate Spectrophotometer (Philadelphia, PA). The
content of sulfated GAGs was calculated by regression analysis. HA content was measured using
an Echelon® competitive ELISA kit (50-1600 ng/ml) (K-1200, Echelon Biosciences Inc., Salt Lake
City, UT) which detected molecules as small as 6.4 kDa. Manufacturer protocol instructions were
followed. Briefly, 100 µl of HA standards and diluted samples were added into a 96-well
incubation plate followed by 50 µl of detection solution, prior to incubation for 1 h at 37◦C.
Following the incubation step, samples (100 µl) were transferred into a detection plate for
competitive binding at 4◦C for 30 min. The plate was then washed three times with 200 µl PBSTween (PBST), before addition of an enzyme-linked antibody and substrate solution. Colorimetric
detection at 405 nm was used to detect the enzyme-substrate system comprised of alkaline
phosphatase/ pNPP phosphatase substrate. The colorimetric signal was inversely proportional to
the HA content in the sample and the concentration. A standard curve with the known amounts of
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HA was used to determine concentration of HA. The total GAG content of the extracted materials
was calculated by addition of the two analyses described above and further confirmed using a
carbazole reaction to measure uronic acid after hydrolysis of GAGs with sulfuric acid, as
previously reported [246–248]. The absorbance of samples was measured at 550 nm and GAG
content was calculated by regression analysis using a HA sodium salt standard curve.

3.6.

GAGs Size Analysis
The molecular weight of GAGs was evaluated by agarose gel electrophoresis based on the

method of Cowman and others with modifications [249]. Agarose gels (0.75% w/v) were prepared
by dissolving 0.3 g of agarose in 36 ml of water using 1.5 min of heating in a microwave oven.
The agarose solution was cooled under running tap water for 3 min and then mixed with 4 ml of
10X TBE buffer to make the final gel volume of 40 ml. Gels of 10 x 6.2 cm were cast in a casting
accessory using an 8-tooth well-forming comb. Before electrophoresis, gels were allowed to set
for at least 1 h. To load samples, the comb was removed and the gel plate was transferred to a BioRad (Hercules, CA) Mini-Sub® Cell GT system which was filled with 290 ml of pre-chilled 1X
TBE buffer. Cells were loaded with samples (3 ug GAGs/ well in ultrapure water) and GAG
standards (HA & CS) which were mixed with 4 µl of 2 M sucrose loading buffer and sample
volume made up to 24 µl with ultrapure water. Select-HA™ HiLadder (5 µl) and LoLadder (5 µl)
were mixed with deionized water (10 µl) and loading buffer (4 µl) before being loaded into a well.
Electrophoresis was carried out at room temperature at a constant voltage of 70 V for 2.5 h using
a Bio-Rad PowerPac™ power supply. The loading buffer tracking dye migrated about 80% of the
gel during this time period. Immediately after the run the gel was placed in approximately 250 ml
of a staining solution containing 0.005% Stains-All in 50% absolute ethanol (stored protected from
light). The gel was stained overnight under light-protective cover at room temperature. For
44

destaining, the gel was transferred to a 10% ethanol solution and stored in the dark for 8 h with at
least one change of destaining solution. Final destaining of any residual background was
accomplished by placing the gel on a light box for a few minutes.

Agarose gel electrophoresis was also performed on all samples after an alternative final
dialysis step using single use micro DispoDialyzers™. Briefly, GAG dry samples were dissolved
in distilled and deionized water (100 µl) and placed in a floating sample chamber that separated
the low molecular weight GAGs (<50 kDa) through a cellulose membrane and into the dialysis
buffer (tap water). Samples were dialyzed with constant stirring for 48 h in 200 ml of buffer with
changes every 2, 5, 15, 30 and 45 h. Samples were recovered into a micro centrifuge tube by
centrifugation (1-2 s) at 1500 rpm. Electrophoresis was performed as described above.

3.7.

Digestion of GAGs by Type-1 Hyaluronidase and Chondroitinase ABC
Digestion of ACS, AFT, ABS and AEB samples by a type 1 bovine testes HAase was

conducted to prove that the stains seen on the previously described agarose gels were truly GAGs.
Phosphate Buffer (300 mM sodium phosphate, pH 5.35 at 37°C) was used to prepare a 0.5 mg/ml
GAG solution which was completely dissolved and kept at 37°C in a water bath. Immediately
before use, a 24,000 U/ml HAase stock solution was prepared by dissolving the enzyme in enzyme
diluent (20 mM sodium phosphate with 77 mM sodium chloride and 0.01% (w/v) BSA, pH 7.0 at
37°C). Ultrapure water was used and pH was adjusted with 1 N NaOH or 1 N HCl. The stock
solution was diluted with enzyme diluent to obtain additional working solutions of 12,000 U and
6,000 U. The final HAase assay concentrations (48, 24 and 12 U/µg sample) were obtained by
mixing 0.5 ml of each GAG solution with 0.5 ml of enzyme solution (24,000, 12,000 or 6,000
U/ml). Incubation was conducted at 37°C with continuous swirling during exactly 20 hours. HAase
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was heat inactivated on a boiling water bath for 10 minutes prior to centrifugation at 10,000 rpm
for another 10 min. Supernatants were collected and stored at -80°C until used.

An enzymatic assay using ChrAse ABC was conducted on ACS GAGs to further confirm
the identity of the purple stains in agarose gels stained with 0.005% Stains-All solution. A GAG
solution in sample diluent (250 mM Tris-HCl and 300 mM sodium acetate with 0.05% (w/v) BSA,
pH 8.0 at 37°C) and a ChrAse ABC solution (0.4 U/ml) in 0.01% BSA were prepared. Working
enzyme solutions (0.2 U/ml and 0.1 U/ml) were prepared from dilutions of the stock solution. The
final ChrAse assay concentrations (0.2, 0.1 and 0.05 U) were obtained by mixing equal parts of
ACS sample solution and enzyme stock or working solutions. Digestion was conducted at 37°C
during 8 h with constant swirling, after which samples were boiled for 10 min, centrifuged at
10,000 rpm during 10 min and stored at -80°C until used. The results of the HAase and ChrAse
ABC assays were evaluated by running all samples in 0.75% agarose gels and staining with
0.005% Stains-All as described previously.

3.8.

Determination of Protein and Mineral Content
Protein content of the solubilized purified GAG extracts was quantified by measuring

absorbance at 562 nm using a Pierce™ Bicinchoninic Acid (BCA) Protein Assay (Philadelphia,
PA). A series of dilutions of known concentrations of bovine serum albumin were used as
standards and assayed alongside the GAG samples. GAG extract samples were prepared for
mineral content by dilution of 100 mg in deionized water (10 ml) and filtration through a 0.22 µm
syringe filter. Concentration determination of the filtered samples was carried out using
inductively coupled plasma atomic emission spectrometry (ICP-AES) at the Louisiana State
University Soil Testing and Plant Analysis Laboratory.
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3.9.

Structure Characterization by FT-IR Spectroscopy
A Bruker (Billerica, MA) Tensor 27 FT-IR spectrometer with a MIRacle™ single

reflection diamond/ZnSe attenuated total reflectance cell (Pike Technologies, Madison, WI) was
employed to obtain FT-IR spectra of lyophilized ACS, AFT, ABS and AEB GAGs. Commercial
HA and chondroitin-4-sulfate powders were analyzed and used as standard spectra. The spectrum
of each compacted dry sample was obtained over 50 scans in the range of 650-4000 cm-1, against
a background spectrum recorded from the clean empty cell at room temperature. Spectral data
analysis was conducted using the OPUS data collection software version 7.2 (Bruker, Ettlinger,
Germany). Atmospheric and baseline corrections were applied to the data which was presented as
wavenumber (cm-1) versus normalized absorbance (min = 0.0 and max = 2.0).

3.10. Cystic Fibrosis Ex-Vivo Scnn1b-Tg Mice Pilot Study
3.10.1 Transgenic Mice Generation and PCR Genotyping
All animal protocols were approved by the Louisiana State University’s Institutional
Animal Care and Use Committee. The transgenic mice used for this experiment were Scnn1b-Tg,
a well-established murine model of CF and COPD [179,250,251]. This C57BL/6N congenic mice
line over-expresses the β-subunit of the ENaC channel which leads to ASL depletion and CF-like
mucus obstruction. Moreover, Scnn1b-Tg mice recapitulate many key features of CF including
high MIP-2, TNF-α, high TGAse activity, and neutrophilia among others [10,164,179,252,253].
Genomic DNA extraction from mice tail tissue was performed and transgene-positive animals
were identified by polymerase chain reaction (PCR) as previously published [179].
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3.10.2 Animal Husbandry
All the Scnn1b-Tg mice used in this study were maintained in hot-washed, individually
ventilated cages on a 12-hour dark/light cycle and were fed regular diet and water ad libitum. Mice
were euthanized after establishment of chronic pulmonary disease, on post-natal day 38.

3.10.3 Trachea Harvesting
Mice (4 females) were euthanized by avertin injection (300 µl/mice) before being laid
down (abdomen up) and disinfected (abdomen, thorax and neck) with 70% ethanol. Using clean
surgical instruments, a horizontal cut from abdomen to neck skin was performed to expose the
thoracic and neck regions prior to exsanguination via dissection of the abdominal aorta and
puncturing of the diaphragm. Trachea were exposed by removal of surrounding tissue and were
removed by dissecting just below the vocal cords and at the carina bifurcation. All trachea were
placed into a 50 ml conical tube containing 10 ml of cold Ham’s F12 media containing antibiotics.
In a sterile laminar flow hood, the trachea and Ham’s F12 media containing antibiotics were
transferred into a 100 mm Petri dish for removal of extraneous tissue (thyroid gland, esophagus,
etc.). Trachea were transferred to a new Petri dish containing Ham’s F12 with antibiotics (10 ml)
and cut open lengthwise to expose the lumen. Finally, trachea were placed in a 50 ml conical tube
containing 10 ml of a solution prepared by mixing 9 ml of cold Ham’s F12 with antibiotics and 1
ml of a filter-sterilized 1% pronase stock solution. The tube was incubated on a rocker overnight
at 4°C. Subsequently, MTEC isolation and primary cell cultures were conducted as previously
described by Lam and others [254] as well as other researchers [255–257] with modifications.
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3.10.4 MTEC Isolation
After overnight incubation, 10 ml of Ham’s F12 media containing 20% FBS and antibiotics
were added to the tube which was then rocked 12 times and let to stand 30 min on ice. Tracheas
were then transferred to a new conical tube containing 10 ml of Ham’s F12 media with 20% FBS
and antibiotics using a Pasteur pipette and rocked 12 times. This step was repeated two more times
and finally the remaining tissue was discarded. The pronase solution along with the three
supernatants were pooled (50 ml total) and kept on ice at all times prior to centrifugation at 500 x
g for 5 min at 4°C in a Heraeus Megafuge 16R centrifuge (Thermo Scientific, Kalkberg, Germany).
The supernatant was discarded and the pellet gently re-suspended and incubated 5 min on ice in
1 ml of a filter-sterilized DNase solution (0.5 mg/ml) prepared by dissolving 1.0 mg of DNase in
1.8 ml of Ham’s F12 media containing antibiotics and 200 µl BSA stock solution (10 mg/ml).
After incubation, the suspension was centrifuged (500 x g for 5 min at 4°C) to discard the
supernatant and gently re-suspend the pellet in 5 ml of filter-sterilized MTEC basic media
containing 10% FBS (Table 3.1). For the removal of fibroblasts, the suspension was plated on a

Table 3.1
MTEC Basic Media (10% FBS) Formulation
Reagent

Final Concentration

DMEM/Ham's F-12 (HEPES) (1:1)
Penicillin-Streptomycin

0.25 µg/ml

HEPES

15 mM

Sodium Bicarbonate

3.6 mM

L-Glutamine

4 mM

Fetal Bovine Serum

10%
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Primaria™ tissue culture dish and incubated at 37°C in an atmosphere of 95% air and 5% CO2 for
4.5 hours. Following incubation, the cell suspension was collected and the plate was rinsed twice
with 4 ml MTEC basic media containing 10% FBS. The cell suspension and washes were pooled
together in a 50 ml conical tube and centrifuged (500 x g for 5 min at 4°C) to discard the
supernatant and re-suspend the pellet in 4.4 ml of filter-sterilized MTEC media containing Y27632
ROCK inhibitor (10 µM) (MTEC+Y27632). Cells were counted (10 µl cell suspension + 10 µl
trypan blue) in a Bio-Rad TC20™ automated cell counter (Bio-Rad Laboratories, Hercules, CA).

3.10.5 MTEC Submerged Culture
Six Transwell™ polyester membrane inserts were coated with 50 µg type I collagen
dissolved in 165 µl of a solution prepared by mixing 0.02N sterile acetic acid and collagen stock
(8.31 µg/µl). The inserts were air-dried in a hood overnight and then exposed to ultraviolet light
for 30 min before being seeded with 300 µl of the previously prepared cell suspension (9.5 x 104
cells/insert). MTEC+Y27632 media (1 ml) (Table 3.2) was fed basally and cells were incubated
overnight at 37°C in an atmosphere of 95% air and 5% CO2. On the first day post-seeding, the
apical media and non-adherent cells were aspirated. The inserts were then washed twice with 1 ml
PBS and transferred to a 6-well plate with previously autoclaved teflon rings. The cultures were
fed every other day with 2.5 ml MTEC+Y27632 media basally and 50 µl apically until confluent
(7 days). The apical surface was washed gently once a week by adding 0.5 ml of PBS to the insert
and carefully aspirating with a Pasteur pipette.

3.10.6 MTEC Differentiation in Air-Liquid Interface Culture
Once confluent, cell cultures were changed to an air-liquid-interface (ALI) in a fresh 6well tissue culture plate for differentiation. The cells were fed basally with 2.5 ml of MTEC media
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Table 3.2
MTEC+Y27632 Media Formulation
Reagent

Final Concentration

DMEM/Ham's F-12 (HEPES) (1:1)
Penicillin-Streptomycin

100 U/ml: 100 mg/ml

Insulin

10 µg/ml

Epidermal Growth Factor

25 ng/ml

Transferrin

5 µg/ml

Bovine Pituitary Extract

30 µg/ml

Retinoic Acid

5x10-8 M

Fetal Bovine Serum

5%

Cholera Toxin

0.1 µg/ml

Y-27632 ROCK inhibitor

10 µM

containing Nu-Serum growth medium supplement (MTEC+NuSerum) every other day during 21
days (Table 3.3). Fresh retinoic acid (5x10-8) was also supplemented to the MTEC+NuSerum
media every other day during the last 14 days of ALI culture. The apical surface was washed gently
once a week by adding 0.5 ml of PBS to the insert and carefully aspirating with a Pasteur pipette.

3.10.7 MTEC Treatment with AEB GAGs
Once cells were differentiated (day 21 of ALI culture) the MTEC cultures were treated
apically with 350 µl of a solution containing 1.43 mg AEB GAGs/ml in 0.9% saline (0.5 mg AEB
GAGs/insert). MTEC cultures treated only with the normal saline (350 µl) were used as a control.
The volume applied apically (350 µl) has been reported in ALI primary tracheal mice [179] and
the treatment solution was sterilized by autoclaving at 121°C for 5 min as previously reported
[258,259]. The GAG concentration to be used for this treatment was estimated using as a guideline
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Table 3.3
MTEC+NuSerum Media Formulation
Reagent

Final Concentration

DMEM/Ham's F-12 (HEPES) (1:1)
Penicillin-Streptomycin

100 U/ml: 100 mg/ml
5x10-8 M

Retinoic Acid
Nu-Serum

2%

the successful concentrations reported by Gavina and others (100 µg HA/ml for 24 h in-vitro and
0.5 mg/mice/day for 7 days in-vivo) [10] and Lieb and others (100 µg HA/ml) [224]. Cultures
were maintained at 37°C in an atmosphere of 95% air and 5% CO2. The treatment was terminated
by aspiration of the supernatant after 24 h and the supernatants were stored at -80°C for further
analysis.

3.10.8 Cell Lysis and RNA Purification
RNA was extracted from MTEC cultures using the RNeasy® Plus Mini Kit (Cat. No.
14134) from Qiagen (Valencia, CA) following the manufacturer’s instructions in an Air Clean®
600 PCR Workstation (BioExpress, Kaysville, UT). Appropriate RNA handling techniques were
applied to avoid contamination. Briefly, cells were disrupted and lysates homogenized using
QIAshredder spin columns (Qiagen Cat. No. 79654) placed in 2 ml micro-centrifuge tubes which
were centrifuged for 2 min at maximum speed in a Thermo Scientific Sorvall™ ST 16R Centrifuge
(Kalkberg, Germany). The homogenized lysates were transferred to gDNA eliminator spin
columns in 2 ml collection tubes and centrifuged for 30 s at 8,000 x g. The flow-through was saved
and one volume of 70% ethanol was added and mixed gently by pipetting. The samples were then
transferred to an RNeasy spin column in a collection tube and centrifuged for 15 s at 8,000 x g to
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discard the flow-through and elute the RNA from the column by centrifugation with 40 µl of
RNase-free water. RNA concentration (260 nm) and purity (A260 /A280) in the eluate (1 µl) were
measured by UV spectrophotometry using the NanoDrop 2000 from Thermo Scientific
(Wilmington, DE) blanked with RNase-free water. RNA samples (2 ng/µl) were submitted to the
LSU School of Veterinary Medicine GeneLab for RNA integrity number calculation (RIN) and
18s and 28s fragment visualization using a Fragment Analyzer™ (Advanced Analytical
Technologies Inc., Ames, IA).

3.10.9 cDNA Generation and PCR Microarray
Purified RNA (0.33 µg) was used to generate cDNA using the RT2 First Strad Kit from
Qiagen which consisted of a genomic DNA elimination step and reverse transcription at 42°C for
exactly 15 min. SYBR® Green based real-time PCR was performed using a murine CF RT2
Profiler PCR Array which profiles the expression of 84 key CF genes involved in neutrophil
chemotaxis, inflammation, immune response and oxidative stress, among others (Table 3.4) in a
96-well plate format. The arrays included a genomic DNA (GDC), reverse-transcription (RTC)
and positive PCR controls (PPC). Manufacturer protocols were followed. PCR was conducted in
a CFX96 Real-Time System equipped with CFX Manager™ Software and automatic threshold
cycle (CT) calculation from Bio-Rad Laboratories (Hercules, CA). The real-time cycler was first
programed to cycle for 10 min at 95°C to activate the HotStart DNA Taq Polymerase. This cycle
was followed by 40 cycles of annealing for 15 s at 95°C and elongation for 1 min at 60°C with
fluorescence data collection. The temperature ramp rate was adjusted to 1°C/s. Finally, a melting
curve (65°C to 95°C at 0.5°C /s for 5 s) analysis was conducted to verify PCR specificity, evident
by a single peak appearing in each reaction at temperatures greater than 80°C. CT values for all
wells were processed with the SABiosciences PCR Array Data Analysis Web-based software. The
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software calculated ΔCT (CT Gene of Interest - CT Housekeeping Gene) based on the B2m
housekeeping gene and then calculated the normalized gene expression values using the formula
2^-ΔCT. The fold-change values were then converted to fold-regulation. The software also
performed a hierarchical cluster analysis of the dataset to generate a gene expression heat map
(fold-regulation >1.5 and p≤0.05) with dendrograms indicating co-regulated genes across arrays.
A heat map for all the 84 genes analyzed was also generated.

Table 3.4
Murine CF RT2 Profiler PCR Array Gene List*
Gene ID
Official Name
CF Modifier Genes
Adipor2
adiponectin receptor 2
Gstm2
glutathione S-transferase, mu 2
Ifrd1
interferon-related developmental regulator 1
Msra
methionine sulfoxide reductase A
Nos3 (eNOS)
nitric oxide synthase 3, endothelial cell
Tcf7l2
transcription factor 7 like 2, T cell specific
CFTR Interactors
Ahsa1
AHA1, activator of heat shock protein ATPase 1
Canx
Calnexin
Cftr
cystic fibrosis transmembrane conductance regulator
Dnaja1
DnaJ heat shock protein family (Hsp40) member A1
Dnajc5
DnaJ heat shock protein family (Hsp40) member C5
Ezr
ezrin
Gopc
golgi associated PDZ and coiled-coil motif containing
Hsp90aa1 (Hspca)
heat shock protein 90, alpha (cytosolic), class A member 1
Hspa4 (Hsp70)
heat shock protein 4
Nme1 (NM23A)
NME/NM23 nucleoside diphosphate kinase 1
Pdzk1
PDZ domain containing 1
Ppp2r4
protein phosphatase 2 regulatory subunit 4
Prkaa1 (Ampk)
protein kinase, AMP-activated, alpha 1 catalytic subunit
Prkaa2
protein kinase, AMP-activated, alpha 2 catalytic subunit
Slc26a3
solute carrier family 26, member 3
CFTR Interactors
solute carrier family 9 (sodium/hydrogen exchanger), member 3
Slc9a3r1
regulator 1
solute carrier family 9 (sodium/hydrogen exchanger), member 3
Slc9a3r2
regulator 2
Snap23
synaptosomal-associated protein 23
54

(Table 3.4 continued)
Gene ID
Official Name
CFTR Interactors
Stx1a
Stx8
Tjp1
Vcp
Ccl12 (MCP-5,
Scya12)
Cxcr2 (IL-8rβ)
Edn1
Ednra
IL-1β
Itgb2
Ace
Adrb2
Alox12b
Cxcl1 (Gro1)
Cxcl3
Defb1
IL-10
IL-6
Mbl2
Pla2g5
Ptgs2 (COX)
S100a8
S100a9
Serpina1e
Tgfb1
Tlr2
Tlr4
Tlr5
Tnf
Tnfrsf11a (Rank)
Tnfrsf1a (Tnfr1)
Clu
Icam1
Lcn2 (NGAL)
Mapk1 (Erk2)
NF-Kβ1

syntaxin 1A
syntaxin 8
tight junction protein 1
valosin containing protein
Neutrophil Chemotaxis
chemokine (C-C motif) ligand 12
chemokine (C-X-C motif) receptor 2
endothelin 1
endothelin receptor type A
interleukin 1 beta
integrin beta 2
Inflammatory Response
angiotensin I converting enzyme
adrenergic receptor, beta 2
arachidonate 12-lipoxygenase, 12R type
chemokine (C-X-C motif) ligand 1
chemokine (C-X-C motif) ligand 3
defensin beta 1
interleukin 10
interleukin 6
mannose-binding lectin (protein C) 2
phospholipase A2, group V
prostaglandin-endoperoxide synthase 2
S100 calcium binding protein A8
S100 calcium binding protein A9
serine (or cysteine) peptidase inhibitor
transforming growth factor, beta 1
tool-like receptor 2
tool-like receptor 4
tool-like receptor 5
tumor necrosis factor
tumor necrosis factor receptor superfamily, member 11a, NF-κβ
activator
tumor necrosis factor receptor superfamily, member 1a
Immune Response
clusterin
intercellular adhesion molecule 1
lipocalin 2
mitogen-activated protein kinase 1
nuclear factor of kappa light polypeptide gene enhancer in B cells 1,
p105
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(Table 3.4 continued)
Gene ID
Official Name
NF-Kβia (IKβα,
Mad3)
Prkce
Tnfsf10 (Trail)
Fas (Tnfrsf6)
IL-7r
Calr
Hspa1a (hsp70A1)
Hspa8
Hsph1 (hsp105)
Adk
Kcne1
Nr4a2 (Nurr1)
Scnn1b
Scnn1g
Dusp1 (Ptpn16)
Gclc
Sftpb
Epsti1
Igfbp5
Itga2
Kit (CD117)
Met
Prtn3
Slpi

Immune Response
nuclear factor of kappa light polypeptide gene enhancer in B cells
inhibitor, alpha
protein kinase C, epsilon
tumor necrosis factor (ligand) superfamily, member 10
Fas (TNF receptor superfamily member 6)
interleukin 7 receptor
Unfolded Protein Response
Calreticulin
heat shock protein 1A
heat shock protein 8
heat shock 105kDa/110kDa protein 1
Ion Binding & Transport
adenosine kinase
potassium voltage-gated channel, Isk-related subfamily, member 1
nuclear receptor subfamily 4, group A, member 2
sodium channel, nonvoltage-gated 1 beta
sodium channel, nonvoltage-gated 1 gamma
Oxidative Stress
dual specificity phosphatase 1
glutamate-cysteine ligase, catalytic subunit
surfactant associated protein B
Other CF Genes
epithelial stromal interaction 1 (breast)
insulin-like growth factor binding protein 5
integrin alpha 2
kit oncogene
met proto-oncogene
proteinase 3
secretory leukocyte peptidase inhibitor

*

Genes might be relevant in more than one CF pathway.

3.10.10

Transglutaminase Activity Assay

Extracellular TGAse activity in MTEC was measured spectrophotometrically (450 nm)
using the TGAse Assay Kit from Sigma-Aldrich (Cat. No. CS1070). Manufacturer’s protocols
were followed. The assay is based on the TGAse catalysis of a covalent bond formation between
a free amine group of poly-L-lysine, which is covalently bonded to a 96-well plate surface, and
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the ƴ-carboxamide group of a biotin substrate buffer. The amount of immobilized biotin was
proportional to the amount of active TGAse.
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CHAPTER 4
RESULTS AND DISCUSSION

4.1.

Yields of Sulfated GAG, HA and Total GAG from Alligator By-products
Waste by-products of farmed alligators 12 to 18-months old with approximate snout to tail

length of 4-feet, had mean weights as reported in Table 4.1. These values represent results from
80 ACS, 400 AFT, 100 ABS and AEB from 200 gator heads. Alligators from different farms and/or
development stage may or may not conform to this data.

Table 4.1
Alligator By-product Processing Results
By-product
ACS
Weight (g)
Meat Yield (% w/w)

(n = 80)

AFT
(n = 100)*

ABS
(n = 100)

AEB
(n = 200)

942.00 ± 109.12

105.84 ± 6.93

68.44 ± 12.46

2.67 ± 0.19

74.34 ± 2.72

-

-

-

Bone Yield (% w/w)
22.46 ± 3.88
Vitreous Humor Yield
25.85 ± 2.24
(% w/w)
Means ± SD are shown. ACS = alligator carcasses, AFT = alligator feet, ABS = alligator
backstraps, AEB = alligator eyeballs. *Average weight of two anterior and two posterior feet is
reported.

The data presented in Table 4.1 can be used by alligator processors to estimate the value
of their by-products if used for GAG extraction and estimate the number of alligators needed to
meet a particular sales need. To the best of our knowledge, this is the first work that reports the
desinewed meat yield (74.34 ± 2.72%) from ACS. This meat, which contained 17.32 ± 0.02% fat
(wet basis) as determined by accelerated hexane extraction, might be a business opportunity if
incorporated into dry protein snacks, sausage, hamburger or pet treat formulations.
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Purified GAGs from farmed alligator by-products were obtained by a series of optimized
physical and chemical processes including removal of myofibrillar proteins and fat, enzymatic
hydrolysis of collagenous protein and purification by dialysis, as well as NaCl-ethanol
precipitation, heat treatment and lyophilization. The sulfated GAG yields (Table 4.2) as
determined by the DMB assay were highest (p ≤ 0.05) in ABS (0.22 ± 0.01 mg/g wet ABS),
followed by AFT, ACS and AEB, in that order. The calibration curve for this assay showed a linear
relation between the absorption at 525 nm of the chondroitin sulfate-DMB complexes versus
concentration of CS in the solution, with a correlation coefficient (R2) of 0.975 as shown in
Figure 4.1.

Absorbance at 525 nm

0.25
0.2
0.15
0.1

y = 0.0033x + 0.0343
R² = 0.975

0.05
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0
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40
CS Concentration µg/ml

50

60

Figure 4.1. Standard curve for sulfated GAG assay.

A quantitative analysis of the GAGs extracted from chicken combs demonstrated a sulfated
GAG concentration (0.2 mg sulfated GAGs/ g wet comb) very similar to our ABS results. The
content was characterized to be mainly DS and CS [120]. In contrast, a study conducted by Luo
and others, evaluated the CS yield of chicken keel cartilage and it was shown that every gram of
wet keel cartilage yielded approximately 24.84 mg of dry CS [125]. Some of the differences that
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might account for the lower sulfated GAG yields obtained in our study compared to keel cartilage
include: sample type (cartilage only), species, slaughter age, extraction process and purification
methods. For instance, the chicken keel cartilage study used a 3.5 kDa MWCO membrane which
might retain more of the typically low molecular weight sulfated GAGs compared to the 14 kDa
MWCO membrane used in our study. Moreover, hyoid, rib, sternum and trachea cartilages from
four year-old Thailand crocodiles have also been found to be rich in CS with contents ranging
from approximately 2.58 to 3.99% on a wet basis [245]. On this research, Garnjanagoochorn and
others performed an enzymatic cartilage hydrolysis with papain and CS purification using NaCl
and CPC. Heat treatment (90-95 °C for 10 min) of cartilage samples was conducted beforehand to
remove meat and connective tissue [245].

Quantitation of HA concentrations by ELISA using a standard curve generated by nonlinear regression analysis (Figure 4.2) revealed yields of 0.60 ± 0.00, 4.62 ± 0.06, 15.31 ± 0.26 and
0.78 ± 0.01 mg per gram of wet ACS, AFT, ABS and AEB, respectively (Table 4.2). The addition
of sulfated GAG and HA concentrations is also presented in Table 4.2 as total GAGs (mg/g byproduct). The total concentration of GAGs was calculated to be 0.60 ± 0.00 (0.06% w/w), 4.72 ±
0.05 (0.47% w/w), 15.53 ± 0.27 (1.55% w/w) and 0.79 ± 0.01 (0.08% w/w) mg/g of wet ACS,
AFT, ABS and AEB, respectively. Non-sulfated HA accounted for 97.87 – 99.48% of the extracted
GAGs and the highest yield per gram was obtained from ABS, followed by AFT, AEB and ACS.
Similar results have been reported for Mediterranean mussels (Mytilus galloprovincialis), in which
~97% of the extracted GAGs were HA [260]. Based on the average by-product weight data
reported in Table 4.1 and the average yields reported in Table 4.2 (average by-product weight x
average total GAG yield), the estimated total GAG yields from one farmed alligator (~4 ft.) are
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Table 4.2
Composition of Alligator GAGs
By-product
Sulfated GAGs
(mg/ g of wet
by-product)
ACS
0.00 ± 0.00c*

HA Content
(mg/ g of wet
by-product)
0.60 ± 0.00d

Total GAGs
(mg/ g of wet
by-product) †
0.60 ± 0.00d

Total GAGs
(mg/ g of wet
by-product) ††
0.63 ± 0.03c

AFT

0.10 ± 0.01b

4.62 ± 0.06b

4.72 ± 0.05b

4.98 ± 0.73b

ABS

0.22 ± 0.01a

15.31 ± 0.26a

15.53 ± 0.27a

16.66 ± 2.34a

AEB
0.01 ± 0.01c
0.78 ± 0.01c
0.79 ± 0.01c
0.83 ± 0.04c
Means ± SD are shown. ACS = alligator carcasses, AFT = alligator feet, ABS =
alligator backstraps, AEB = alligator eyeballs.
*
Means that do not share a letter within a column are significantly different (p≤0.05).
†

Total GAGs (mg) = Sulfated GAGs (mg) + Hyaluronic Acid (mg)

††

Total GAGs measured by the 96-well carbazole reaction.
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Figure 4.2. HA competitive ELISA standard curve

highest in ABS (1.06 g/backstrap), while ACS (0.57 g/carcass) and AFT (0.50 g/4 feet) have
similar contents, and AEB (0.004 g/2 eyes) have the lowest yield. These results are equivalent to
approximately 2.13 g GAGs from each alligator. In 2014, a total of 341,887 farmed alligators were
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slaughtered in Louisiana [39] which means that an estimated 0.73 tons (728.22 Kg) of GAGs could
have been extracted with over 97% accounting for HA.

The 96-well assay for uronic acid carbazole reaction has been reported to be a sensible and
reproducible method for the determination of complex uronic acid containing GAGs [248]. In our
samples, the carbazole assay further confirmed the presence of uronic-acid containing
polysaccharides (Table 4.2), however there was a slight (4.76 - 6.78%) overestimation of the total
GAG content compared to the additive procedure (sulfated GAG concentration + HA
concentration). A study by Frazier and others highlighted the reproducibility of the 96-well
carbazole assay, however it observed that it may overestimate GAGs in the presence of salts [261].
This salt effect might account for the difference in total GAG results due to an increase in
background absorbance. The calibration curve of the HA standard performed in a 96-well plate is
shown in Figure 4.3.

Vertebrate tissues and invertebrate species have been largely studied as rich sources of
sulfated and non-sulfated GAGs [65,120,122–125,245,247,262–264]. For instance, several
publications have reported yields from chicken combs ranging from 1 to 4 mg hexuronic acid/ g
wet tissue [120,121,123]. Our higher yields per gram from AFT and ABS indicate that these byproducts are promising when compared to this well-established source of HA. GAGs have also
been successfully extracted from marine by-products such as shark fin cartilage (~2.45% on a wet
basis) and ray cartilage (~1.83% on a wet basis). Differences in the yields compared to our research
are mainly driven by the fact that cartilages were manually separated and cleaned prior to GAG
extraction which results in higher yields compared to our direct processing of samples as collected
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Figure 4.3. Calibration curve for HA standard carbazole reaction

from the alligator facilities [245]. Comparison of yields to other marine sources such as salmon
nasal cartilage (24% w/w on a dry basis) and dogfish cartilage (1.5% w/w on a wet basis) face the
same constraint [265,266]. Furthermore, in Mediterranean mussels the dry weight yield of GAGs
was estimated to be 6.1 mg/g (0.6% w/w). These were obtained after defatting with organic
solvents, extracting by proteolytic treatment and precipitation with NaCl and ethanol [260]. Recent
work on marine sources of GAGs, reflects that processes for marine GAG extraction are focused
on obtaining sulfated GAGs [263,264], however lumpsucker fish (Cyclopterus lumpus) dorsal
humps have a yield of ~40% purified GAGs from wet starting mass and the majority of the extract
was dominated by non-sulfated high molecular weight HA [247]. Attempts have also been made
to determine the concentration of GAGs in the body wall of sea cucumbers (Stichopus japonicus).
Kariya and others reported it to be only 0.03% [267]. In the light of the currently available data for
animal by-product sources, the process proposed for GAG extraction from ACS, AFT and ABS is
promising due to the high abundance of these by-products in Louisiana, to the high percentage of
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non-sulfated HA in the extracts and the high yields per gram obtained particularly in ABS and
AFT. The main by-product disposed from alligator processing by weight is ACS, therefore its high
availability in addition to the potential added-value of desinewed meat justify its use for GAG
extraction despite its lower yield compared to ABS and AFT.

Even with a lower GAG content per alligator, AEB must be considered a viable source of
HA due to its highly pure abundance in the vitreous humor which facilitates its extraction and
purification, compared to ACS, AFT and ABS. Moreover, the AEB HA yield obtained in this study
(0.78 mg/g eyes or ~3.02 mg/g vitreous humor) is much higher than the concentrations reported
by other studies. This result is at least two times higher than reported contents in bovine vitreous
humor (0.3 mg/g), swordfish vitreous humor (0.055 mg/g), shark vitreous humor (0.3 mg/g) and
pig vitreous humor (0.04 mg/g) [124,268]. The differences in GAG contents are thought to be
mainly due to differences between species and extraction procedures.

4.2.

Agarose Gel Electrophoresis of Alligator GAGs
The molecular weight of GAGs is an important determinant of its biological activity. To

estimate the molecular weight of ACS, AFT, ABS and AEB GAGs, agarose gel electrophoresis
was performed following an improved method reported by Cowman and others with slight
modifications [249]. Figure 4.4 shows the separation of GAG standards and the polydisperse
molecular weight nature of ACS, AFT, ABS and AEB GAGs on a 0.75% agarose gel stained with
Stains-All. We observed a primarily blue staining on all samples (lanes 2-5) indicating the presence
of HA. The polydisperse distribution of molecular weight in HA from animal tissues was evident
in ACS (~110-1600 kDa), AFT (~70-510 kDa), ABS (~15-1100 kDa) and AEB (~25-1600 kDa)
GAGs. CS was visualized on ACS (<70 kDa) as a purple-reddish smear. The characteristic staining
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Figure 4.4. Electrophoresis of ACS, AFT, ABS and AEB GAGs on
a 0.75% agarose gel. Lane 1: mixture of Select-HA HiLadder and
LoLadder (1648, 1138, 940, 667, 509, 310, 213, 111 and 30.2 kDa);
lane 2: ACS GAGs; lane 3: AFT GAGs; lane 4: ABS GAGs; lane 5:
AEB GAGs; lane 6: HA salt; lane 7: Chondoitin-4-sulfate salt from
bovine trachea; lane 8: mixture of Select-HA HiLadder and
LoLadder.

of sulfated GAGs with Stains-All has been previously reported [269]. The presence of sulfated
fractions was not observed in AFT, ABS or AEB which might indicate that they migrated faster
due to their low molecular weight and ran off the gel. Sulfated GAGs from sea cucumbers have a
molecular weight of 18 kDa [267].
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Agarose gel electrophoresis of the GAG samples was also conducted after dialysis in a
small volume (100 µL) sample chamber with a cellulose membrane against water. Figure 4.5
indicates that dialysis during 48 hours successfully removed HA below ~28 kDa and LMW
sulfated GAGs from all samples (see arrow on Figure 4.5). Based on the target market
requirements, further purification and specific molecular weight separation can be conducted using
size exclusion chromatography. Our results show that ACS, AFT, ABS and AEB contain HA of
molecular weights comparable to the HA sizes reported from other animal and microbial sources.
The molecular weights of HA purified from Mediterranean mussels and eggshells was estimated
to be about 200 kDa and 50-250 kDa, respectively [246,260,270]. HMW-HA has been reported in
vitreous humor from fish (1600-2000 kDa) [124]. HA from rooster combs has been reported to
have a size ranging from 750 to 1200 kDa [123,271]. Microbial fermentation sources report HA
molecular weights of 538-900 kDa, with wound healing properties proven in the 538 kDa fractions
[127,246]. Due to their content of beneficially bioactive HMW-HA and MMW-HA, alligator byproducts have a significant commercial potential.

4.3.

Enzymatic Assays
Alligator GAG samples were digested with HAase from bovine testes as negative controls

to prove that the stainings seen on Figure 4.4 are truly representative of GAGs. Our results (Figure
4.6) show that increasing concentration of HAase resulted in increasing depolymerization of the
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Figure 4.5. Electrophoresis of ACS, AFT, ABS and AEB GAGs on
a 0.75% agarose gel after dialysis (50 kDa MWCO). Lane 1: mixture
of Select-HA HiLadder and LoLadder (1648, 1138, 940, 667, 509,
310, 213, 111 and 30.2 kDa); lane 2: ACS GAGs; lane 3: AFT
GAGs; lane 4: ABS GAGs; lane 5: AEB GAGs; lane 6: HA salt;
lane 7: Chondoitin-4-sulfate salt from bovine trachea; lane 8:
mixture of Select-HA HiLadder and LoLadder.

GAG samples which proves the presence of HA and CS in the extracts. HAase randomly
hydrolyzes 1,4-linkages between GlcNAc and GlcA in HA and 1,4-linkages between GalNAc or
sulfated GalNAc and GlcA in all types of CS at an optimum pH of 4.5-6.0 [272]. HA degradation
patterns were similar in all samples with increasing concentrations of HAase resulting in increased
HA hydrolysis seen as stains with lower molecular weight or lighter colored bands (downward
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Figure 4.6. Electrophoresis of ACS, AFT, ABS and AEB GAGs on a 0.75% agarose gel
after HAase digestion. In all gels lane 1: mixture of Select-HA HiLadder and LoLadder;
lane 2: 0 U/µg sample; lane 3: 12 U/µg sample; lane 4: 24 U/µg sample; lane 5: 48 U/µg
sample; lane 6: HA salt; lane 7: Chondoitin-4-sulfate salt from bovine trachea; lane 8:
mixture of Select-HA HiLadder and LoLadder.

arrows on Figure 4.6). ABS showed overall HA degradation above 700 kDa and below 33 kDa,
however some concentration was seen around 300-400 kDa in the 12 and 24 U/µg treatments (ABS
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lanes 3 and 4). This might be due to accumulation of hydrolyzed HA chains in that particular
molecular weight or due to transglycosylation. Transglycosylation activity of HAse in the presence
of 6 to 12 monomer HA units has been previously reported to yield HA oligosaccharides at a pH
~7 and salt content below 0.5M [273,274].

ChrAse ABC was used to catalyze the degradation of polysaccharides containing 1,4 and
1,3 linkages. This effect was observed on both non-sulfated and sulfated GAGs in ACS (downward
arrows on Figure 4.7). The GAGs hydrolyzed by ChrAse ABC include C4S, C6S, DS and HA
[275,276]. Even though HA is degraded at a lower rate, this effect was clear in our assay (Figure
4.7). ChrAses A, C, AC and ABC act upon HA, however ChrAse B is specific for cleavage of DS
[277]. Our results show that the purple stains observed in the agarose gels corresponded to some
type of CS. Moreover, dialysis or size exclusion chromatography might be better options to
preserve HMW and MMW HA during the elimination of LMW GAGs.

4.4.

Protein and Mineral Contents of Alligator By-product GAGs
Extracts from ACS, AFT, ABS and AEB were analyzed for presence of residual protein by

using the BCA assay at 562 nm. Most of these by-products are high in muscle and/or collagenous
protein content [245]; therefore, a sequential pepsin and papain methodology was conducted to
yield a clear solution after a total of 16h at 40◦C and 60◦C, respectively. The protein content results
in the different GAG extracts are shown in Figure 4.8. Previously reported protein content values
for GAG extracts from animal sources using diverse proteolysis methods are varied. The protein
content of GAGs purified from chicken keel cartilage by papain digestion (44 mg papain/g dry
matter)
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Figure 4.7. Electrophoresis of ACS GAGs on a 0.75% agarose gel
after ChrAse digestion. Lane 1: mixture of Select-HA HiLadder and
LoLadder (1648, 1138, 940, 667, 509, 310, 213, 111 and 30.2 kDa);
lane 2: ACS GAGs + 0 U ChrAse; lane 3: ACS GAGs + 0.05 U
ChrAse; lane 4: ACS GAGs + 0.1 U ChrAse; lane 5: ACS GAGs +
0.2 U ChrAse; lane 6: HA salt (1500-2200 kDa); lane 7: Chondoitin4-sulfate salt from bovine trachea; lane 8: mixture of Select-HA
HiLadder and LoLadder.
during 6 h at 60◦C, has been estimated to be 1.8 g/100 g dry product (1.8%) [125]. Furthermore,
GAGs isolated from the body wall of sea cucumbers by proteolytic digestion using actinase at a
concentration of 50 mg/g of body wall protein, yielded extracts with 3.1% protein content [267].
These results are within the range of the ones obtained in our study. Moreover, extraction of low
protein and high purity HA from fish eyeballs has been reported using a combination of optimized
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steps including: ultrafiltration-diafiltration, protein electrodeposition, resolubilization in a
hydroalcoholic medium and precipitation in alkaline hydroalcoholic solution. AEB extracts in our
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Figure 4.8. Protein content in alligator by-product GAG extracts

study are similarly of low protein content and high purity (~99%). The AEB protein content is also
similar to the results of Vijayabaskar and Vaseela which reported the protein content of brown
marine algae (Sargassum tenerrimum) sulfated GAG extracts to be 0.86 ± 0.42% [278]. Protein
contents of up to 23.08% have been reported in HA salt from S. zooepidemicus and its wound
healing properties have been demonstrated [127].

The main problem in HA purification is the elimination of diverse proteins that may be
allergenic in some applications [279]. For injection applications (dermal fillers), the ideal final
protein concentration should be around ~5-10 µg of protein/ mg HA and standards become more
tolerant for topical, perfusion or oral intake applications [124]. Although the specifications of the
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European and British Pharmacopoeia require 0.1-0.3% protein in HA [246,280], in the United
States commercially available HA has been reported to contain up to 4.7% protein [281]. Based
on this information, AEB may have potential for use in osteoarthritis visco-supplements,
ophthalmic viscoelastic adjuvants, aesthetic surgery adjuvants, eye drops and topical preparations
for wound and burn healing, among others. With the current protein contents, ACS (1.8%), AFT
(2.65%) and ABS (3.68%) GAG extracts could be used for research applications and potentially
animal nutrition applications. An evaluation of the impurities in HA from different sources was
conducted by Shieldlin and others. HA powders isolated from rooster comb, bovine vitreous
humor, and human umbilical cord were purchased from Sigma Chemical Company. All the
samples contained some amount of protein. The highest levels were detected in HA from human
umbilical cord (47.7 µg/mg HA) and bovine vitreous humor (36.2 µg/mg HA) [281]. The protein
content in commercial human umbilical cord HA is ~30% higher than in ABS which has the
highest protein content among alligator samples. ACS, AFT and AEB also have lower protein
impurities than the ones reported for commercial HA from human umbilical cord and bovine
vitreous humor. To the best of our knowledge, there is currently no standard of identity or reference
standards for HA or sodium hyaluronate in the United States, however protein contents in alligator
GAGs might need to be further reduced to comply with European medical grade or cosmetic grade
standards.

The process described in Figure 3.1 includes four unit operations that mainly influence the
final protein concentration. Namely, removal of muscle proteins with 0.2N NaOH, pepsin and
papain digestion, dialysis filtration and NaCl-ethanol precipitation of GAGs. This process could
be further optimized or new processes such as electrodeposition, filtration through activated
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charcoal or size exclusion chromatography could be incorporated keeping in mind up-scalability
and economic feasibility. It must be kept in mind that further processing is likely to reduce the
molecular weight of the extracted materials. For instance, LMW-HA (125 kDa) with no protein
content has been extracted and purified from commercial eggshells (5.3 mg HA/ g eggshell) using
acetic acid extraction, isopropanol precipitation and silica gel-activated charcoal purification
[246].

Mineral contents in alligator by-product GAGs are predominantly sodium as measured by
ICP-AES (Figure 4.9). The contents were similar in ACS (13.92 ± 0.20 mg/100 mg dry extract),
AFT (10.64 ± 0.20 mg/100 mg dry extract) and ABS (11.03 ± 0.20 mg/100 mg dry extract) with
sodium accounting for over 97% in all three extracts. These results were expected in the extracts
due to the separation of GAGs with NaCl (Figure 3.1). This is in close agreement with what is
reported in current product specifications from Sigma-Aldrich (St. Louis, MO) for hyaluronic acid
sodium salt from bovine vitreous humor (3-10% Na). The usage rate of NaCl (2M) in this study
(Figure 3.1) was determined based on the efficiency of GAG recovery. Addition rates of 1M, 1.5M,
2M and 4M were evaluated, however no significant increases in GAG yields were observed after
2M. NaCl (4M) and CPC (10%) were also evaluated in combination and no increase in GAG
recovery was observed (data not shown). Murado and others reported that NaCl concentrations
higher than 1.5M should be used for optimal GAG recovery. Lower values of NaCl might lead to
extracts with higher protein concentrations [124]. AEB GAGs purified without NaCl precipitation,
as reported in Figure 3.2, had lower total mineral contents (0.27 ± 0.03 mg/100 mg dry extract)
and cations (Na+ and K+) were the predominant minerals. Physiologically, HA is found in the salt
form bound to cations [282]. Trace levels of other minerals such as Phosphorus, Sulfur and
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Calcium were also detected in all samples. The origin of these is thought to be the bones, claws
and calcified scales in ACS, AFT and ABS, respectively.
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Figure 4.9. Mineral content in alligator by-product GAG extracts

4.5.

FTIR Spectra of Alligator By-product GAGs
The FTIR-ATR spectra in the spectral range of 650-4000 cm-1 for GAGs from ACS, AFT,

ABS and AEB are presented in Figure 4.10. The assignment of FTIR bands for the various samples
is given in Table 4.3. Commercial Streptococcus sp. HA and bovine trachea CS standards were
used as references for data analysis and peak identification. All samples and standards displayed a
strong absorption peak in the range of 3258 cm-1 to 3289 cm-1 suggesting the stretching of -NH or
-OH in the uronic acid COOH group as expected in GAGs [94]. Lower absorption peaks near 3078
cm-1 for samples and 3099 cm-1 for standards have been previously identified as the -NH and C=O
combination in the amino sugar of GAGs while minor stretches at the range of 2890 and 2980
suggest -CH stretching [127,246,283,284]. The FTIR spectra of alligator samples also revealed the
presence of characteristic C=O vibrations associated with primary amides between 1627 cm-1 and
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Figure 4.10. FTIR-ATR spectra of alligator GAGs

75

Table 4.3
Assignment of FTIR Bands for Standards and Alligator GAGs
FTIR Bands
Functional Groups

Wavenumber (cm-1)
HA STD

CS STD

ACS

AFT

ABS

AEB

1

O-H or N-H stretching

3271*

3267

3258

3285

3272

3289

2

N-H with C=O combination

3095

3099

3078

3078

3079

3078

3

C-H stretching

2890

2891

2935

2959

2937

2980

4

C=O carboxyl amide I

-

-

1635

1631

1632

1627

5

Amide II

1602

1604

1546

1539

1538

1575

6

N-H deformation

1490

1442

1452

1452

1452

1453

7

C-O with C=O combination

1407

1409

1399

1399

1393

1404

8

C-O-H deformation

1375

1375

-

-

-

-

9

S=O stretching

-

1222

1255

1241

1245

1243

10

C-O-H stretching, C-O and C-O-C

1148

1155

-

-

1154

1121

11

1080

1080

1080

1080

1080

1081

12

1034

1023

1030

1029

1028

1042

13

O-H deformation

947

923

922

921

921

925

14

C-O-C stretching

895

887

882

-

-

-

15

C4S Sulfate group

-

855

-

-

-

855

*

Peak absorbance wavenumbers (cm-1) are shown. HA STD = hyaluronic acid standard, CS STD = chondroitin sulfate standard,
ACS = alligator carcasses, AFT = alligator feet, ABS = alligator backstraps, AEB = alligator eyeballs.
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1635 cm-1. Although these peaks were not observed in the HA or CS standards, they have been
reported in haddock (Theragra chalcogramma) and other marine species GAGs as C=O stretching
in N-acetyl groups of amino sugars or C=O stretching in peptide residues [94,284,285]. The
secondary amide peaks were centered around 1600 cm-1 for HA and CS standards and were found
at lower wavenumbers for alligator samples (1538 cm-1 to 1575 cm-1). A peak in the range of 1222
cm-1 and 1255 cm-1 was observed mainly in the CS standard while alligator samples showed minor
absorption in this region which is supported by the quantified sulfated GAGs content reported in
Table 4.1. Accordingly, absorption in the 1200 cm-1 to 1250 cm-1 range was not observed in the
HA standard [94,284]. Peaks in the range of 1000 cm-1 and 1200 cm-1 (C-OH, C-O and C-O-C)
have been reported to be fingerprints of pyranose rings which are the building blocks of GAGs
[286,287]. Below 1000 cm-1, -OH deformations and C-O-C stretches were suggested by Alkrad
and others [283]. Absorption at 855 cm-1 confirms the presence of chondroitin-4-sulfate [245]. In
aggregate, the fingerprint functional groups and structures related with GAGs were identified in
the 650-4000 cm-1 FTIR spectra. Moreover, the FTIR fingerprints of ACS, AFT, ABS and AEB
reveal broad similarities between them and the findings are comparable with the spectra reported
in past studies on animal sourced GAGs.

AFT GAG samples were also submitted to Thermo Fisher Scientific for collection of FTIR
spectra (Figures 4.11 and 4.12). The FTIR spectra presented a high similarity to the one depicted
in Figure 4.10, however a sharper definition of the fingerprint region may be due to the use of
newer and more sensitive equipment. Quenching of some fingerprint signals and the presence of
amide peaks was thought to be due to presence of residual collagen protein or peptides.
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Figure 4.11. FTIR spectra of AFT GAGs (top) and streptococcal HA-salt (bottom).
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4.6.

Scnn1b-Tg MTEC Gene Expression Analysis
To evaluate the potential of AEB GAGs (Figure 4.12) to regulate gene expression in CF-

like MTEC ex-vivo cultures, we took advantage of the well-established Scnn1b-Tg mice line that
over-expresses the β-subunit of the ENaC channel and presents constitutive airway inflammation.
The isolation of Scnn1b-Tg MTECs yielded 3.49x105 live cells/trachea which were successfully
proliferated in a submerged culture and differentiated at ALI into an intact monolayer with a
cobblestone morphology as previously reported [281]. Murine epithelial primary cultures with
these characteristics are suitable for the investigation of airway diseases and evaluation of novel
therapies [257]. The ALI Transwell™ culture system allowed culturing of the MTEC in conditions
closer to the in-vivo physiological orientation which is an advantage compared to conventional
media submerged cultures [254].
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Figure 4.12. Electrophoresis of AEB GAGs used for MTEC
treatment after dialysis (50 kDa MWCO) and autoclaving
(121.1°C for 5 min). Lane 1: mixture of Select-HA HiLadder and
LoLadder (1648, 1138, 940, 667, 509, 310, 213, 111 and 30.2
kDa); lanes 2-4: AEB GAGs (10 µg/lane); lane 5: HA salt
standard.
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RNA free of any major contaminants was successfully purified from MTEC control and
treated cultures as indicated by the A260 /A280 of 2.07 ± 0.00 and 2.08 ± 0.01, respectively (Table
4.4). These RNA quality parameters impact downstream reverse transcription procedures the most
[289]. High RIN results (Table 4.4) in addition to sharp peaks and bands of rRNA 5S, 18S and
28S fragments are indicators of RNA with very low degradation (Figure 4.13). RIN values above
5.5 have been reported to yield high quality outcomes in rt-PCR [290]. Quality control assays of
the cDNA generation efficiency, genomic DNA contamination, and overall PCR performance
were passed by all samples. All the arrays presented similar (p≤0.05) reverse-transcription
efficiencies (average RTC – average PPC ≤ 5) which indicate that the generated data is suitable
for comparison (Table 4.4). Genomic DNA contamination did not contribute to the fluorescence
signals captured during real-time PCR (GDC CT ≥ 35) and the overall PCR reproducibility within
and between arrays passed the manufacturer’s approval parameters (Table 4.4).

Table 4.4.
RNA Extraction and PCR Control Results
Reagent

Control (saline)

AEB GAGs Treated

RNA A260/A280 Ratio‡

2.07 ± 0.00*a

2.08 ± 0.01a

RIN††

9.03 ± 0.06a

8.93 ± 0.15a

>35

>35

CT GDC§
φ

Reverse-Transcription Efficiency

3.93 ± 0.06

a

PCR Array ReproducibilityΩ

4.11 ± 0.26a
Pass

*

Means that do not share a letter within a row are significantly different.

‡

A ratio of ~2 is generally accepted as "pure".

††

Values range from 1 (totally degraded) to 10 (intact). RIN ≥7 is ideal.

GDC CT ≥35 is equal to "Pass".
Average RTC CT - Average PPC CT ≤ 5 is equal to "Pass".
Ω
If average PPC CT within an array is 20±2 and average PPC CT of any two arrays is not more
than 2 different from one another, then the sample receives a "Pass".
§

φ
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The gene expression analysis of PCR microarray data was conducted by setting a lower
limit of detection (CT< 35), a ΔRn threshold above the automatically calculated background signal,

Control

AEB GAG Treated
28S
28S
18S
18S

Ladder

5S

5S
Ladder

Figure 4.13. Capillary electrophoresis electropherograms and gels of RNA extracted from
control and AEB-GAG treated Scnn1b-Tg MTEC.

a fold-regulation threshold (1.5) and normalization to the B2m housekeeping gene which was the
most stably expressed across the evaluated samples (ΔAverage C T <1). The genes that were not
detected (9.52%) in at least one of the microarrays were not included in the analysis, namely
Alox12b, Ccl12, Cxcr2, Il1b, Il10, Il6, S100a8, Serpina1e, Slc26a3. Seventy five (89.29%) of the
genes analyzed were detected and a heat map depicting their differential expression in MTEC
cultures is shown in Figure 4.14. After treatment with 0.5 mg AEB GAGs, MTEC gene expression
was differentially regulated when compared to controls. Without a fold-regulation threshold,
32.00% (24 genes) of the genes were significantly (p≤0.05) down-regulated and 4.00% (4 genes)
up-regulated, while the rest of the genes was not significantly (p>0.05) down (42.67%) or upregulated (21.33%) (Figure 4.15A). The overall shifts observed in the expression of 75 genes are
indicative of the multiple signaling properties associated with HA in murine lungs through the
81

Figure 4.14. Non-supervised hierarchical clustering heat map of the
differentially expressed genes in treated and untreated (control)
Scnn1b-Tg MTEC in ALI culture.
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AEB GAG Treated vs Untreated
A
32.00%

4.00%

42.67%

21.33%

32.00%

4.00%

22.67%

6.67%

B

34.67%

Figure 4.15. Distribution of gene regulation due to AEB GAGs treatment of
Scnn1b-Tg MTEC in ALI culture. A) Plot of significantly (p≤0.05) and not
significantly regulated genes. B) Plot of significantly (p≤0.05) and not
significantly regulated genes with a 1.5-fold regulation threshold.
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CD44, RHAMM and/or TLR4 [78,79,291,292], however for a more significant view of the
potential effects of AEB GAGs in gene expression, a volcano plot including a 1.5 fold-regulation
threshold is shown in Figure 4.15B. Under this criteria, 34.67% of the genes remained unchanged
after AEB GAG treatment and the percentage of significantly (p≤0.05) regulated genes remained
unchanged. Evaluation of the gene expression of wild-type MTEC cultures is important for further
confirmation and understanding of these results. Figure 4.16 presents a non-supervised hierarchical
clustering heat map with dendrograms which graphically presents differences in the gene
expression patterns between treated and control cell cultures. Genes are clustered based on
similarities in their expression patterns and not according to known functional similarities. In order
of regulation magnitude, the significantly (p≤0.05) up-regulated (>1.5-fold) genes were the Slpi,
Cxcl1, and Lcn2 (Table 4.5). Following the same criteria, the down-regulated genes were Kit,
Hsph1, Itga2, Ace, Hsp90aa1, Tgfb1, Slc9a3r2, Ezr, Nfkb1, Slc9a3r1, Igfbp5, Tjp1, Adipor2,
Prkaa1, Gopc, Prkce, Prkaa2, Ppp2r4, Hspa8, Sftpb, Nr4a2, Tlr4, Calr, and Tcf712. Other genes
with non-significant (p>0.05) fold-regulation above 2- fold included S100a9 (2.18-fold; p-value=
0.0778302), Ptgs2 (-3.78-fold; p-value= 0.065190), Edn1 (-2.69-fold; p-value= 0.123140), Dusp1
(-2.28-fold; p-value= 0.062676), and Dnajc5 (-2.07-fold; p-value= 0.056502). Preliminary
interpretations of these gene expression regulations suggest potential anti-protease, antiinflammatory, and ion-transport homeostatic effects of AEB GAG treatment on Scnn1b-Tg MTEC
ex-vivo cultures.

The 6.38-fold upregulation of Slpi in AEB GAG treated cells compared to control untreated
cultures was the highest and most significant (p=0.0019) gene regulation observed in this study
(Table 4.5). In human vaginal epithelial cells, Dusio and others reported a marked increase in Slpi
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Figure 4.16. Non-supervised hierarchical clustering heat map with dendrograms indicating co-regulated genes of the significantly
(p≤0.05) regulated (>1.5 fold) genes in treated and untreated (control) Scnn1b-Tg MTEC in ALI culture.
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Table 4.5.
Genes differentially expressed in HA treated vs untreated Scnn1b-Tg MTEC*
Gene

Function

p-value

Foldregulation

Up-Regulated
Slpi

Protection of epithelial tissues from serine proteases

0.0019

6.38

Cxcl1

Antimicrobial gene. Neutrophil chemoattractant

0.0349

3.54

Lcn2

Antibacterial activity & oxidative stress protection

0.0398

2.10

Down-Regulated
Kit

MAST cell adhesion to airway epithelia

0.0036

-3.88

Hsph1

Stress response

0.0110

-3.61

Itga2

Matrix metalloproteinase-1 positive regulation

0.0066

-3.59

Ace

Vasoconstrictor & pro-inflammatory mediator

0.0011

-3.35

Hsp90aa1

Endoplasmic reticulum stress response

0.0027

-3.35

Tgfb1

Fibrosis development & inflammatory response

0.0094

-3.33

Slc9a3r2

Trans-epithelial sodium/hydrogen absorption

0.0105

-3.25

Ezr

Actin linking to the apical membrane & mucin secretion

0.0305

-3.23

Nfkb1

Positive regulator of inflammation

0.0471

-2.96

Slc9a3r1

Trans-epithelial sodium/hydrogen absorption

0.0181

-2.84

Igfbp5

Fibrosis development & ECM production

0.0030

-2.78

Tjp1

Regulation of cell polarity & tight junction regulation

0.0148

-2.69

Adipor2

Regulation of AMPK & PPAR-alpha metabolisms

0.0031

-2.56

Prkaa1

Metabolic regulation

0.0498

-2.42

Gopc

Ion channel binding

0.0277

-2.41

Prkce

Immune response modulation

0.0023

-2.35

Prkaa2

Metabolic regulation

0.0188

-2.28

Ppp2r4

Homeostatic balance of cell metabolism & signaling

0.0359

-2.18

Hspa8

Protein folding & cellular homeostasis

0.0290

-1.94

Sftpb

Surfactant surface formation

0.0273

-1.94

Nr4a2

Modulation of inflammation & metabolism

0.0458

-1.92

Tlr4

Modulation of inflammation & immunity

0.0114

-1.85

+

Calr

Ca2 binding & regulation of surface protein expression

0.0333

-1.79

Tcf7l2

Glucose metabolism & type 2 diabetes susceptibility

0.0193

-1.69

* Genes with significant (p≤0.05) fold-regulation greater than 1.5-fold are presented.
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transcription after LMW-HA (<200 kDa and 0.2% w/v in media) treatment for 18 h [293]. The
secretory leukocyte protease inhibitor is a serine anti-protease encoded by the Slpi gene and it is
known to inhibit elastase, cathepsins, trypsin and chymotrypsin [294,295]. Defects in airway
mucosal defense, including disruption of the homeostatic protease/anti-protease balance,
contribute to the pathogenesis of obstructive pulmonary disease in CF [296], therefore offsetting
this imbalance is one of the therapeutic goals in CF management [297,298]. Therapeutic
approaches have included administration of Slpi and synthetic anti-proteases [295,296]. An in-vivo
study with sheep exposed to human elastase reported a blockage of elastase-related airway
responses after treatment with aerosolized HA (150 and 300 kDa) [11]. It has also been reported
that a single aerosol exposure (20 mg/mice for 50 min) to streptococcal HA (100 kDa) reduced
elastase-induced airspace enlargement in mice and prevented elastic fiber injury in-vitro [300].
Overall, positive results regarding HA protection of airway fibers and regulation of acute lung
injury have been reported [301], however there are no known reports of HA regulation of the Slpi
gene in airway epithelial cells as observed in our results. HA has also been reported to immobilize
and regulate other important components of the airway defense mechanism such as the serine
protease tissue kallikrein and lactoperoxidase. Regulation of these enzymes is important for
homeostasis at the apical mucosal surface [79]. The down-regulation of Itga2 (-3.59-fold) further
supports the potential capacity of AEB GAG treatment to mediate the protease/anti-protease
imbalance characteristic of CF. Integrin α2β1 is a positive gene expression regulator of the MMP1 [302] which is a serine collagenase known to be differentially upregulated during acute and
chronic lung diseases compared to healthy patients [303,304]. Inhibition of expression or
activation of MMPs has been proposed as a therapeutic strategy in lung CF and other chronic lung
diseases [303,305,306].
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Tgfb1 was down-regulated -3.33-fold in AEB GAG treated MTEC (Table 4.5) and it
encodes the transforming growth factor-β which promotes fibrosis through the deposition of ECM,
promotes inflammation and modulates immune responses in a cellular and environmental contextdependent manner [307]. Polymorphisms in the Tgfb1gene have been associated to an accelerated
decline in lung function of patients with CF [308]. Microarray analyses with cDNA have shown
that Tgfb1 upregulation alters the expression of multiple genes important for the initiation of acute
lung injury in nickel exposed mice [309]. A recent (2016) review highlights the fact that fibrosis
is generally viewed as failed wound healing and that it can eventually lead to loss of lung function
[310]. This supports the positive implications of Tgfb1 and Igfbp5 (-2.78-fold) downregulation in
treated cells (Table 4.5). Studies have demonstrated the increased expression of Igfbp5 in mice
lung tissue after bleomycin-induced fibrosis [311], idiopathic pulmonary fibrosis in human lung
sections [312], and severe emphysema of smokers in a chromosomal region strongly linked to
FEV1 [313]. The results discussed so far and the currently available literature point towards an
important role of AEB GAGs in Snn1b-Tg epithelial tissue protection from excessive degradation
by proteases and excessive remodeling in airway diseases [314]. The prominent roles of Slpi antiprotease activity and Tgfb1-related inflammation in wound healing and skin diseases like psoriasis
suggest that AEB GAGs might also have potential in the treatment of inflammatory skin diseases
[315–317].

In addition to protease inhibition, the secretory leukocyte protease inhibitor encoded by
Slpi, has also been shown to inhibit inflammatory responses via a number of different mechanisms
including competition with p65 for binding of NF-κβ which in turn prevents its activation and
inhibition of neutrophil degranulation [296,318]. In our study, anti-inflammatory effects were
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observed in epithelial cells treated with AEB GAGs which could be dependent or independent of
Slpi regulation. Down-regulation of Ace (-3.59-fold), Nfkb1 (-2.96-fold), Nr4a2 (-1.92-fold), and
Tlr4 (-1.85-fold) (Table 4.5) and directionally but not significantly (p>0.05) of Ptgs2
(Cyclooxygenase-2) (-3.78-fold) support this observation. Angiotensin II is a vasoconstrictor
related to hypertension, however independently from this role it is also a potent pro-inflammatory
mediator and inhibition of its converting enzyme encoded by Ace has been beneficial in mice
pulmonary disease models and for patients with inflammatory diseases [319,320]. Asthmatic
patients report higher (p≤0.05) serum levels of angiotensin II converting enzyme compared to
controls and it has been proposed that regulating this imbalance may aid in recovering the system’s
inflammatory and ROS homeostasis [321]. Interestingly, an association has been reported between
the severity of CF and the undesirable effects of the Ace gene in Tunisian CF patients [322].
Furthermore, angiotensin II is associated with activation of NF-κβ-mediated genes in lung injury
[323,324]. There is consensus in the fact that NF-κβ-mediated chronic inflammation is a prominent
feature of CF lung disease and its downstream activation of IL-8 secretion and neutrophil influx
promote progression of COPD and emphysema [325,326]. Our data further suggests potential antiinflammatory properties of AEB GAGs through the modulation of Prkce (-2.35-fold) and Nr4a2
(-1.92-fold) (Table 4.5). Protein kinase C encoded by Prkce is involved in many signal
transduction events for several pathways including immune response, bacterial induced
inflammation, development of COPD and formation of neutrophil extracellular traps (NET) [327–
330]. The protein kinase C dependence for formation of NETs and the pro-inflammatory potential
of excessive NET formation in CF has been demonstrated [328,331,332]. Therefore the Prkce
downregulation observed in our study is valuable in supporting the anti-inflammatory effects of
AEB GAGs. Nr4a2 is a nuclear receptor regulated by Nfkb1, Tgfb1, Ptgs2, and Tlr4 and it
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modulates inflammation via MMP regulation [333,334]. In a synoviocyte cell line, microarray
analyses showed that Nr4a2 regulates the transcription of the Il8 gene (+5.04-fold increase vs
control) [335] and it is also a key regulator of inflammation in rheumatoid arthritis in vitro [336].
A highlight of the arthritis study is the remarkable anti-inflammatory effect of streptococcal HA
(257 kDa) via the attenuation of mRNA expression of Nr4a1, Nr4a1, Nr4a3 and Mmp genes.
Immune and inflammatory responses can also be mediated by negative regulation of TLRs which
play a role in lung inflammation and risk of emphysema development [337–339]. In our study, all
TLRs analyzed (Tlr2, Tlr4, and Tlr5) were downregulated, however only Tlr4 passed the
thresholds for statistical significance (p≤0.05) and fold-regulation (>1.5-fold). This is of interest
in our study due to the report that NE can induce Il8 gene expression via Tlr4 in human bronchial
epithelial cells [340]. It has also been reviewed that in healthy epithelial cells HMW-HA is sensed
by TLR2 and TLR4 and it protects the integrity of the epithelium by preventing apoptosis. On the
other hand in injured tissues, HMW-HA is degraded and shorter fragments sensed by TLRs which
results in inflammatory gene expression [291]. This offers an insight into the potential use of
continued HMW-HA treatment in diseased airways as a novel therapeutic strategy and area of
research for the modulation of inflammation.

Kit is a gene that encodes a receptor tyrosine kinase which contributes to mast cell adhesion
to structural airway epithelial cells [341] and it showed the largest down-regulation (-3.88-fold) of
all the genes differentially expressed in our study (Table 4.5). Targeting the inhibition of mast cell
interactions with structural airway cells has been proposed as a novel approach to the treatment of
asthma [341]. Chronic mast cell activation has undesirable effects on airway function,
inflammation, and re-modelling in asthma pathophysiology through the production of TNF-α, IL-
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1β, IL-6 and IL-13 mediated by TLR4 activation [342,343]. In CF and idiopathic pulmonary
fibrosis, the concentration of tryptase and chymase positive mast cells were increased in lung areas
showing increased inflammation or fibrosis compared to control individuals. These alterations in
mast cell concentrations correlated positively to lung function parameters [344]. Moreover, mast
cell serine proteases (tryptase and chymase) have the ability to activate MMP-1 [345]. In our study,
down-regulation of Ptgs2 (cyclooxygenase-2), which is upregulated in CF, may also reduce the
release of the inflammatory mediator histamine from mast cells [346,347]. The potential positive
effects of Kit downregulation after AEB GAG treatment are in agreement with the antiinflammatory and protease/anti-protease balance mediation effects previously discussed.
Altogether, these effects may be contributing to the apparent lower stress response in AEB GAG
treated MTEC.

Heat shock proteins (HSP) are mammalian stress proteins produced in response to various
forms of cellular stress [348]. HSPs also appear to be upregulated with worsening inflammation
as previously reported in asthma epithelial cells [349,350]. Our results show that Hsph1 (HSP105),
Hsp90aa1 (HSP90α) and Hspa8 (HSP70) were all significantly (p≤0.05) down-regulated in AEB
GAG treated cells by -3.61, -3.35 and -1.94-fold, respectively compared to control cultures (Table
4.5). This a positive outcome given that elevated levels of HSP27. HSP70 and HSP90α in COPD
are markers for immune activation and tissue destruction [351]. Accordingly, HSP70 and IL-8
levels in lung epithelial tissues of patients with COPD were significantly increased compared to
patients without COPD and the results positively correlated with the severity of the disease [352].
HSP105 exists as a complex associated with HSP70 [348]. AEB GAG treated MTEC might also
have been protected against oxidative stress as suggested by Lcn2 upregulation (2.20-fold) (Table
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4.5). Under conditions of oxidative stress, upregulation of Lcn2 has a protective role against free
H2O2 radicals and its upregulation can be cancelled by the addition of antioxidants which further
supports its proposed role [353,354]. In agreement with these findings, Lcn2 has been reported to
be up to 9.8-fold upregulated in bronchial tissues of individuals exposed to sulfur mustard gas
compared to controls and an advantageous role in decreasing ROS stress has been proposed [355].
Human neutrophil lipocalin-2 is also a key antibacterial component of the innate immune system
[356] and a biomarker of acute exacerbation in CF [357]. We speculate that in the present study
the upregulation of Lcn2 may have been protective as a result of nitrosative and oxidative stresses
which can occur in Scnn1b-Tg mice as mentioned by Livraghi and others [358]. Cxcl1 (3.54-fold)
was also upregulated in our study (Table 4.5) and its expression is known to be high in nonasthmatic airway smooth muscle cells in vivo which limits mast cell chemotaxis [359]. Marcos
and others recently reported that levels of Cxcl1are high in BAL of Scnn1b-Tg mice compared to
wild-type littermates, however there was no correlation between its upregulation and free levels of
DNA or parameters of pulmonary obstruction [360]. Furthermore, this chemokine ligand has been
reported to contribute to host defense by modulating neutrophil-related bactericidal functions
[361]. Increased mRNA expression of several genes related to antimicrobial functions has been
reported after HA treatment of vaginal epithelial cells [293]. To evaluate if the observed
upregulated antimicrobial gene expressions were not due to contaminants present in the AEB GAG
preparations (i.e. lipopolysaccharide), the AEB GAG solution used for treatment was analyzed for
E.coli/coliforms and total aerobic counts (data not shown). Aerobic counts (100-10-3 duplicate
plates) of the autoclaved treatment solution showed no growth or presence of coliforms, however
aerobic counts of samples prior to autoclaving showed 68 CFU/ml (100 dilution). It is possible that
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lipopolysaccharides from dead bacteria in the solution may have contributed to the upregulation
of Cxcl1 to some extent [362].

Slc9a3r2 (-3.25-fold) and Slc9a3r1 (-2.84-fold) were differentially down-regulated by
AEB GAG treatment in Scnn1b-Tg MTEC (Table 4.5). These genes encode Na+-H+ antiporter
regulators in the sub-apical membrane of epithelial cells where they play a central role in pH
regulation and Na+ homeostasis. Moreover, CFTR and Na+-H+ antiporters in renal epithelial cells
have been shown to interact via a regulatory complex that includes ezrin, encoded by Ezr, and
protein kinase A, encoded by Prkaa [363,364]. Ezr (-3.23-fold), Prkaa1 (-2.42-fold) and Prkaa2
(-2.28-fold) were also downregulated by AEB GAG treatment (Table 4.5). These observations
raise the possibility that AEB GAGs may help modulate the increased Na+ influx in Scnn1b-Tg by
downregulating Na+-H+ antiporter regulators as well as other components of their regulatory
complex. In this manner, the airway epithelia could potentially maintain a more optimal ASL
[365]. A Joint Location-Scale Test very recently highlighted Slc9a3r1, Slc9a3r2, and Ezr for their
previously unknown role in contributing to CF lung disease [366]. Moreover, Ezr is highly
expressed in the bronchi of humans with chronic airway diseases and it has been demonstrated that
it is essential in NE-induced mucin exocytosis which can lead to airway obstruction and bacterial
colonization [367]. BAL secreted mucin content is increased in Scnn1b-Tg mice [358]. Prkaa1
and Prkaa2 encode the adenosine mono-phosphate (AMP)-activated kinase (AMPK). AMPK is
an important regulator of cellular energy homeostasis and [368] and it can be activated by hypoxia,
oxidative stress , and hyperosmotic stress [369,370]. Altogether, the down regulation of Slc9a3r1,
Slc9a3r2, Ezr, Prkaa1 and Prkaa2 indicate that AEB GAGs may be mediating Na+ homeostatic
balance and improvements on the condition of Scnn1b-Tg MTEC ASL ex-vivo [371].
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Tight junctions between epithelial cells control paracellular movements of water, ions , and
solutes, regulate cell polarity and even play a role in airway protection from bacterial infection
[372–375]. It has been proposed that hypertonic saline solutions increase water transport into the
ASL which promotes MCC [376]. The suggested mechanism of this action is the opening of the
tight junctions between epithelial cells which may increase paracellular water transport into the
airway lumen [377]. In the context of an ex-vivo model using cells over-expressing Na+ channels,
our observed downregulation of the tight junction protein Tjp1 (-2.69-fold vs control) (Table 4.5),
along with the Na+ balance regulation previously described, may be another indicator of
optimization of the ASL conditions through enhanced paracellular permeability. CF airway
epithelial cells in vitro have tighter tight junctions than healthy cells and [378], however like in
our study, effects in-vivo in the presence of bacterial insults may cause a different expression of
Tjp1 and other associated proteins [168,372]. Reports on the effects of HA on tight junctions are
varied. In human tracheal epithelial cells at ALI, HA (40 KDa) has been reported to enhance Tjp1
expression and functionality [379], however in human tracheal-bronchial epithelial cells exposed
to cigarette smoke at ALI, HA (<70 kDa) has been reported to disrupt the tight junctions [380].

Other genes that were downregulated with AEB GAG treatment were: Adipor2 (-2.56fold), Gopc (-2.41-fold), Ppp2r4 (-2.56-fold), Sftpb (-1.94-fold), Calr (-1.79-fold), and Tcf7l2 (1.69-fold). Adipor2 (-2.56-fold) (Table 4.5) which encodes for a receptor of adinopectin, has tissue
and environmental-dependent anti- and pro-inflammatory effects [381]. Adinopectin has been
proposed as an inflammatory biomarker in COPD due to its rise during exacerbations [382],
however human and murine studies are still inconclusive regarding its role in inflammation [383].
Gopc also known as the Golgi-associated PDZ is a protein involved in vesicle trafficking and is
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also a negative regulator of CFTR membrane surface levels [384]. Suppression of Gopc has been
proposed as a pharmacological target as an approach to retaining CFTR at the apical membrane
[385]. Furthermore, a logistic regression of whole blood gene expression in smoking and nonsmoking individuals identified Gopc as one of the top five genes that predict smoking status [386].
Ppp2r4 is a CFTR modifier gene that encodes a regulatory subunit of protein phosphatase 2A and
it is associated with CFTR deactivation and correlates positively with a worse progression of FEV1,
lung clearance index and effective specific airway resistance in CF patients [387]. In our study,
the role of Ppp2r4 downregulation remains unclear given the fact that protein phosphatase 2A
signaling has shown a critical role in countering inflammatory and proteolytic responses after
cigarette smoke exposure in mice [388]. The Sftpb gene has shown contradicting results in studies
in Chinese and German populations. In the Chinese population it protected subjects from COPD
and increased FEV1 [389], however in Germany a splice variant of Sftpb increased risk of acute
respiratory failure in COPD [390]. This gene is key to epithelial surfactant homeostasis and is
known to be overexpressed in CF chronic rhinosinusitis and lipopolysaccharide-induced injury
[391]. In a 3-year study, surfactant protein B concentrations increased 213% from year 1 to 3 in
CF patients’ BAL and this correlated positively to decrease in lung function. Interestingly,
surfactant proteins A, C and D concentrations remained unchanged during the 3-year period but
there was a progressive loss of their function [392]. In our Scnn1b-Tg ex-vivo study, Sftpb may
have been downregulated due to a better monolayer hydration which might contribute to make
surface tension lowering less critical. Calreticulin is a protein encoded by the Calr gene and it is
involved in Ca2+ binding as well as protein folding, maturation and trafficking [393]. In COPD
and CF airways, endoplasmic reticulum stress and its Ca2+ stores (calreticulin) promote Ca2+dependent hyper-inflammatory responses [394,395]. Some elements of this response are positive
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such as protective Ca2+ -enhanced MCC, however others such as Ca2+-dependent IL-8 secretion
are undesirable [396]. Calr downregulation by AEB GAG treatment of MTEC may further
contribute to ameliorating the inflammatory phenotype of these cultures.

The last downregulation (p≤0.05; >1.5-fold) observed in this study was related to the Tcf7l2
gene (-1.69-fold) (Table 4.5). This gene confers increased risk of diabetes mellitus on the general
population and modifies age of onset in CF [15,397]. Tcf7l2 is postulated to play a role in the
function of the beta cells of pancreatic islets [398] and an in vivo study on mice suggested that
decreased expression of Tcf7l2 confers reduction of diabetic susceptibility via regulation of the
metabolism of glucose and lipids [399].

TGAse activity in the MTEC culture supernatants after AEB GAG treatment was evaluated
with a method that offers a detection limit of 0.03 mU TGAse/ml. A linear standard curve
(R2=0.992) with triplicate readings in the 0.03 to 0.35 mU/ml range was developed, however no
TGAse activity was detected in any of the samples. Further studies are necessary to elucidate the
role of TGAse in the airways of Scnn1b-Tg mice.

Finally, it is important to mention that the amount of AEB GAGs (0.5 mg/insert of an
extract containing >98.5% HA (~30-1600 kDa)) used in our experiment is much higher than the
innate concentrations previously reported in mice BAL (<5 ng/ml in healthy ice and 100-120 ng/ml
in ozone-exposed mice) [400]. This dose should be enough to compete with any HA present in the
MTEC ASL and to gain access to cell surface receptors. Furthermore, it has been reported that
concentrations of CS are low and HS is not detectable in airway secretions, and thus it is unlikely

96

that any innate presence of these GAGs in MTEC ASL contributes or confounds the results
reported here [380].
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CHAPTER 5
CONCLUSIONS AND FUTURE STUDIES

In this research, GAGs were extracted and characterized for the first time from farmed
Alligator mississippiensis. The extraction and purification methods applied are commonly used to
purify GAGs and collagen from various animal tissues and sources [260,401–403], however byproduct to solvent ratios, protein removal methods and dialysis times were modified or added for
GAG extraction from alligator waste carcasses, feet and backstraps. Moreover, a process for GAG
extraction from alligator eyeball vitreous humor was developed. Of the by-products studied
carcasses were the bulkiest (942.00 ± 109.12 g/ farmed alligator) and had a total GAG content of
0.60±0.00 mg/g wet carcass, however backstraps had the highest (p≤0.05) GAG yield (15.53±0.27
mg/g wet backstrap) and they were easier to extract. This was due to the much less complex nature
of the backstrap compared to the structure and composition of carcasses, feet and eyeballs. The
GAGs extracted from all four by-products studied add up to ~2.13 g GAGs per harvest-size (~24
cm belly-width) farmed alligator or an estimated GAG production of ~0.73 tons/year in Louisiana
alone based on the 2014 farm-raised harvest data. This indicates that alligators are a potentially
high yield source of GAGs, which compares favorably to marine sources that have been studied
and that are generally perceived as “clean” [263]. All extracts contained 0.72-3.68% protein and
eyeball extracts had the lowest protein content therefore posing the lowest risk of hypersensitivity
in downstream applications. FTIR revealed spectra showing characteristic animal GAG features
with which included -OH, -NH and -CH signals, as well as amide signals originated from the
residual protein content of the samples. The GAGs in all samples were predominantly (>97%) nsGAGs or HA with a poly-disperse MW ranging from ~30 to 1600 kDa after a final micro-dialysis
unit operation. We encountered abundance of HMW and MMW GAGs in Alligator
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mississippiensis by-products which offers a new potential to improve waste management practices
and increase revenue in the Louisiana alligator industry through their marketing in the US$1 billion
global HA market [33] for biomedical, cosmetic, human nutrition and animal nutrition
applications.

The results of the Scnn1b-Tg MTEC ex-vivo gene expression analysis suggest that alligator
eyeball GAGs (0.5 mg/ 12 mm insert) may be effective in recovering the protease/anti-protease
balance through regulation of Slpi (+6.38-fold) and Itga2 (-3.59-fold); reducing inflammation
through regulation of Kit (-3.88-fold), Ace (-3.35-fold), Nfkb1 (-2.96-fold), Nr4a2 (-1.92-fold),
and Tlr4 (-1.85-fold); and regulating ASL osmotic homeostasis through regulation of Slc9a3r2
(-3.25-fold), Slc9a3r1 (-2.84-fold)1, Ezr (-3.23-fold), Prkaa1 (-2.42-fold), and Prkaa2 (-2.28fold). The regulation of this triad of key factors in dehydrated airways may have supported an
apparent lower stress condition as indicated by the downregulation of Hsph1 (-3.61-fold),
Hsp90aa1 (-3.35-fold) and Hspa8 (-1.94). In conclusion, although the ex-vivo responses to AEB
GAGs in Scnn1b-Tg MTEC may not be fully predictive of the responses in humans or other
animal models, our findings indicate the potential importance of AEB GAGs in ameliorating some
of the negative responses of dehydrated airways in CF. These pilot study results also justify future
studies to explore other cosmetic or biomedical applications of alligator GAGs which include but
are not limited to: : wound repair, tumorigenesis, lung injury repair, skin humectation, healing of
equine joint disease and canine arthritis care.

It would also be productive to focus future studies deriving from this research on the
industrial up-scalability to pilot and commercial scale of the processes proposed in Figures 3.1 and
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3.2, as well as their financial feasibility. It would also be relevant to evaluate the content and
characteristics of the GAGs contained in the by-products of other Louisiana animals such as
catfish, Asian carp, oysters, nutria, and others.
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